Thromboprophylaxis for trauma patients. by Barrera, Luis M et al.
Barrera, LM; Perel, P; Ker, K; Cirocchi, R; Farinella, E; Morales
Uribe, CH (2013) Thromboprophylaxis for trauma patients. Cochrane
Database of Systematic Reviews, 3 (3). CD008303. ISSN 1469-493X
Downloaded from: http://researchonline.lshtm.ac.uk/856572/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
Thromboprophylaxis for trauma patients (Review)
Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2013, Issue 3
http://www.thecochranelibrary.com
Thromboprophylaxis for trauma patients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Prophylaxis vs No prophylaxis, Outcome 1 Deep Venous Thrombosis (DVT). . . . . 39
Analysis 1.2. Comparison 1 Prophylaxis vs No prophylaxis, Outcome 2 Pulmonary Embolism (PE). . . . . . . 40
Analysis 1.3. Comparison 1 Prophylaxis vs No prophylaxis, Outcome 3 Mortality. . . . . . . . . . . . . 41
Analysis 1.4. Comparison 1 Prophylaxis vs No prophylaxis, Outcome 4 Bleeding. . . . . . . . . . . . . 42
Analysis 2.1. Comparison 2 Mechanical prophylaxis vs No prophylaxis, Outcome 1 DVT. . . . . . . . . . . 43
Analysis 2.2. Comparison 2 Mechanical prophylaxis vs No prophylaxis, Outcome 2 PE. . . . . . . . . . . 44
Analysis 2.3. Comparison 2 Mechanical prophylaxis vs No prophylaxis, Outcome 3 Mortality. . . . . . . . . 45
Analysis 2.4. Comparison 2 Mechanical prophylaxis vs No prophylaxis, Outcome 4 Bleeding. . . . . . . . . 46
Analysis 3.1. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 1 DVT. . . . . . 47
Analysis 3.2. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 2 PE. . . . . . . 48
Analysis 3.3. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 3 Mortality. . . . 49
Analysis 3.4. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 4 Bleeding. . . . . 50
Analysis 3.5. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 5 Major bleeding. . 51
Analysis 3.6. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 6 Minor bleeding. . 52
Analysis 4.1. Comparison 4 LWMH vs UH, Outcome 1 DVT. . . . . . . . . . . . . . . . . . . . 52
Analysis 4.2. Comparison 4 LWMH vs UH, Outcome 2 PE. . . . . . . . . . . . . . . . . . . . . 53
Analysis 4.3. Comparison 4 LWMH vs UH, Outcome 3 Mortality. . . . . . . . . . . . . . . . . . 54
Analysis 4.4. Comparison 4 LWMH vs UH, Outcome 4 Bleeding. . . . . . . . . . . . . . . . . . . 54
Analysis 4.5. Comparison 4 LWMH vs UH, Outcome 5 Major bleeding. . . . . . . . . . . . . . . . 55
Analysis 4.6. Comparison 4 LWMH vs UH, Outcome 6 Minor bleeding. . . . . . . . . . . . . . . . 55
Analysis 5.1. Comparison 5 Mechanical + pharmacological prophylaxis vs Pharmacological, Outcome 1 DVT. . . . 56
Analysis 5.2. Comparison 5 Mechanical + pharmacological prophylaxis vs Pharmacological, Outcome 2 PE. . . . 57
Analysis 5.3. Comparison 5 Mechanical + pharmacological prophylaxis vs Pharmacological, Outcome 3 Mortality. . 58
Analysis 5.4. Comparison 5 Mechanical + pharmacological prophylaxis vs Pharmacological, Outcome 4 Bleeding. . 59
Analysis 6.1. Comparison 6 Mechanical + pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 1 DVT. 59
Analysis 6.2. Comparison 6 Mechanical + pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 2 PE. . 60
Analysis 6.3. Comparison 6 Mechanical + pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 3Mortality. 61
Analysis 7.1. Comparison 7 Thigh-calf vs Calf-foot, Outcome 1 DVT. . . . . . . . . . . . . . . . . 61
Analysis 7.2. Comparison 7 Thigh-calf vs Calf-foot, Outcome 2 PE. . . . . . . . . . . . . . . . . . 62
Analysis 7.3. Comparison 7 Thigh-calf vs Calf-foot, Outcome 3 Mortality. . . . . . . . . . . . . . . . 63
Analysis 7.4. Comparison 7 Thigh-calf vs Calf-foot, Outcome 4 Bleeding. . . . . . . . . . . . . . . . 63
Analysis 8.1. Comparison 8 Prophylaxis vs No prophylaxis (sensitivity analysis), Outcome 1 DVT. . . . . . . . 64
Analysis 8.2. Comparison 8 Prophylaxis vs No prophylaxis (sensitivity analysis), Outcome 2 PE. . . . . . . . 65
Analysis 9.1. Comparison 9 Mechanical prophylaxis vs No prophylaxis (sensitivity analysis), Outcome 1 DVT. . . 65
Analysis 9.2. Comparison 9 Mechanical prophylaxis vs No prophylaxis (sensitivity analysis), Outcome 2 PE. . . . 66
Analysis 10.1. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 1 DVT. . . . . . . . . . . . 66
Analysis 10.2. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 2 PE. . . . . . . . . . . . 67
Analysis 10.3. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 3 Mortality. . . . . . . . . . 67
iThromboprophylaxis for trauma patients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.4. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 4 Bleeding. . . . . . . . . . 68
Analysis 10.5. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 5 Major Bleeding. . . . . . . . 68
Analysis 10.6. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 6 Minor Bleeding. . . . . . . . 69
Analysis 11.1. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis), Outcome 1
DVT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Analysis 11.2. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis), Outcome 2
PE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Analysis 11.3. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis), Outcome 3
Mortality. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Analysis 11.4. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis), Outcome 4
Bleeding. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Analysis 11.5. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis), Outcome 5
Major bleeding. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Analysis 11.6. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis), Outcome 6
Minor bleeding. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
72APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
76CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
76DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
76DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iiThromboprophylaxis for trauma patients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Thromboprophylaxis for trauma patients
Luis M Barrera1, Pablo Perel2, Katharine Ker2, Roberto Cirocchi3, Eriberto Farinella4, Carlos Hernando Morales Uribe1
1Department of General Surgery, Universidad de Antioquia, Medellin, Colombia. 2Cochrane Injuries Group, London School of
Hygiene & Tropical Medicine, London, UK. 3Department of General Surgery, University of Perugia, Terni, Italy. 4General and
Colorectal Surgery, Lister Hospital - East and North Herts NHS Trust, Stevenage, UK
Contact address: Luis M Barrera, Department of General Surgery, Universidad de Antioquia, Street 67 N 53-108, Medellin, Colombia.
luismbarrera@cable.net.co. bluis73@hotmail.com.
Editorial group: Cochrane Injuries Group.
Publication status and date: New, published in Issue 3, 2013.
Review content assessed as up-to-date: 30 April 2009.
Citation: Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH. Thromboprophylaxis for trauma patients. Cochrane
Database of Systematic Reviews 2013, Issue 3. Art. No.: CD008303. DOI: 10.1002/14651858.CD008303.pub2.
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Trauma is a leading causes of death and disability in young people. Venous thromboembolism (VTE) is a principal cause of death.
Trauma patients are at high risk of deep vein thrombosis (DVT). The incidence varies according to the method used to measure the
DVT and the location of the thrombosis. Due to prolonged rest and coagulation abnormalities, trauma patients are at increased risk
of thrombus formation. Thromboprohylaxis, either mechanical or pharmacological, may decrease mortality and morbidity in trauma
patients who survive beyond the first day in hospital, by decreasing the risk of VTE in this population.
A previous systematic review did not find evidence of effectiveness for either pharmacological or mechanical interventions. However,
this systematic review was conducted 10 years ago and most of the included studies were of poor quality. Since then new trials have
been conducted. Although current guidelines recommend the use of thromboprophylaxis in trauma patients, there has not been a
comprehensive and updated systematic review since the one published.
Objectives
To assess the effects of thromboprophylaxis in trauma patients on mortality and incidence of deep vein thrombosis and pulmonary
embolism. To compare the effects of different thromboprophylaxis interventions and their effects according to the type of trauma.
Search methods
We searched The Cochrane Injuries Group Specialised Register (searched April 30 2009), Cochrane Central Register of Controlled
Trials 2009, issue 2 (The Cochrane Library), MEDLINE (Ovid) 1950 to April (week 3) 2009, EMBASE (Ovid) 1980 to (week 17)
April 2009, PubMed (searched 29 April 2009), ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) (1970 to
April 2009), ISI Web of Science: Conference Proceedings Citation Index-Science (CPCI-S) (1990 to April 2009).
Selection criteria
Randomized controlled clinical trials involving people of any age with major trauma defined by one or more of the following criteria:
physiological: penetrating or blunt trauma with more than two organs and unstable vital signs, anatomical: people with an Injury
Severity Score (ISS) higher than 9, mechanism: people who are involved in a ’high energy’ event with a risk for severe injury despite
stable or normal vital signs. We excluded trials that only recruited outpatients, trials that recruited people with hip fractures only, or
people with acute spinal injuries.
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Data collection and analysis
Four authors, in pairs (LB and CM, EF and RC), independently examined the titles and the abstracts, extracted data, assessed the risk
of bias of the trials and analysed the data. PP resolved any disagreement between the authors.
Main results
Sixteen studies were included (n=3005). Four trials compared the effect of any type (mechanical and/or pharmacological) of prophylaxis
versus no prophylaxis. Prophylaxis reduced the risk of DVT in people with trauma (RR 0.52; 95% CI 0.32 to 0.84). Mechanical
prophylaxis reduced the risk ofDVT (RR=0.43; 95%CI 0.25 to 0.73). Pharmacological prophylaxis wasmore effective thanmechanical
methods at reducing the risk of DVT (RR 0.48; 95% CI 0.25 to 0.95). LMWH appeared to reduce the risk of DVT compared to UH
(RR 0.68; 95% CI 0.50 to 0.94). People who received both mechanical and pharmacological prophylaxis had a lower risk of DVT (RR
0.34; 95% CI 0.19 to 0.60)
Authors’ conclusions
We did not find evidence that thromboprophylaxis reduces mortality or PE in any of the comparisons assessed. However, we found
some evidence that thromboprophylaxis prevents DVT. Although the strength of the evidence was not high, taking into account existing
information from other related conditions such as surgery, we recommend the use of any DVT prophylactic method for people with
severe trauma.
P L A I N L A N G U A G E S U M M A R Y
Preventing death from blood clots, the formation of blood clots and blood clots in the lungs in people who have had physical
trauma
Thromboembolism (unwanted clotting of the blood) is a frequent complication in people who have experienced physical trauma
and is also an important cause of death. The type of trauma, association with vascular injuries, and prolonged hospital bed rest are
known risk factors for the development of deep vein thrombus (clot in veins of lower extremities) that can travel (embolize) to the
lungs and cause death. Because of this it is usually recommended that people who have had major trauma are given mechanical or
pharmacological treatments to prevent their blood forming unwanted blood clots. Mechanical interventions can include compression
stockings, an air-filled plastic tube that presses around the leg, a metal blood clot filter placed inside a vein; pharmaceutical drugs include
unfractionated heparin, low weight molecular heparin, anticoagulants (e.g. warfarin), antiplatelet drugs (e.g. aspirin) and others. Sixteen
studies involving 3,005 people are included in this review. We did not find strong evidence that either mechanical or pharmacological
interventions reduce death or clots travelling to the lungs, but we found some evidence that they can prevent clots from forming in the
legs.
B A C K G R O U N D
Description of the condition
Trauma is one of the leading causes of death and disability in
young people (Evans 2003).Worldwide, about five million people
die as a result of trauma every year (WHO 2008). For patients
who reach hospital within one hour of trauma (called the ’golden
hour’), blood loss and traumatic brain injury are the main causes
of death (Sauaia 1995). For patients who survive beyond the first
day, multiple organ failure, central nervous system (CNS) injury
and venous thromboembolism (VTE) are the principal causes of
death (Acosta 1998).
Trauma patients are at known risk of entering into a hypercoagu-
lable state (intrinsic alterations in the nature of the blood itself ).
Mechanisms of hypercoagulability in the trauma setting include
stasis, vessel wall dysfunction and alterations in clotting mecha-
nisms (Virchow’s triad). Injured patients are often immobilized
after high-energy trauma. Being in a static position causes a re-
duction in venous blood returns and a decrease in the supply of
oxygen and nutrients to endothelial cells. In addition, endothelial
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damage caused by direct trauma to the vessels causes the exposition
of tissue factor bearing cells. This initiates a procoagulant factor
that amplifies the coagulant response. These tissue factor bearing
cells move to the cell surface of the platelets, which produces a
propagation of the signal through the accumulation of throm-
bin, activated cofactors and more platelets, inducing thrombosis
(Hoffman 2001).
On the other hand, trauma patients experience a reduction of fibri-
nolytic pathways that seems to result from increased plasminogen
activator inhibitor (PAI) 1. PAI 1 inhibits tissue plasminogen acti-
vator (tPA) and thus decreases the production of plasmin (Rogers
1995; Kelsey 2000). Coagulation abnormalities and the reduced
ability to use the muscular pump of the calf in the injured pa-
tient can produce deep venous thrombosis (DVT) in the inferior
and superior extremities (Spaniolas 2008). When the thrombus
extends to the proximal segments, there is an increased risk of clot
migration to the lungs and a fatal outcome (Geerts 2008).
Trauma patients are at high risk for DVT, with an incidence of
11.8% to 65% (Sevitt 1961; Geerts 1994; Velmahos 2000). The
incidence varies according to the method used to measure the
DVT and the location of the thrombosis. Incidence of thrombosis
in the thigh (proximal DVT) is estimated at 18% (Geerts 1994).
The incidence of pulmonary embolism (PE) is estimated be-
tween 1.5%and 20% (Shackford 1988;O’Malley 1990; Velmahos
2000). Many risk factors for DVT and PE in trauma patients
have been identified such as spinal cord injury, lower extremity
and pelvic fractures, need for surgical procedures, increasing age,
femoral venous line insertion or surgical repair of venous injuries,
prolonged immobility, long duration of hospital stay, severity of
the trauma, and mechanism of injury (Geerts 1994; Knudson
1994; Frezza 1996; Velmahos 2000; Cipolle 2002; Rogers 2002;
Meissner 2003).
Description of the intervention
Thromboprophylaxis describes any intervention used to prevent
the development of VTE, and can be categorized into mechanical
and pharmacological interventions.
External mechanical devices such as graded compression devices
or intermittent pneumatic compression (IPC) have been shown
to be effective in preventing DVT, but they cannot be used in
patients with lower extremity trauma (Fisher 1995; Elliott 1999;
Velmahos 2000). Internal mechanical devices are used to prevent
the migration of thrombus from DVT to the lungs, thus prevent-
ing PE. One such device is the inferior vena cava filter (IVCF)
which may be particularly useful in trauma patients because of the
risk of ongoing bleeding at injured sites (McMurty 1999).
Pharmacological thromboprophylaxis was first described in the
1940s by Bauer 1944, and since then a number of interventions
have been proposed. The anticoagulant effect of unfractionated
heparin (UH) is initiated by the activation of antithrombin III
(ATIII). The ATIII/heparin complex inactivates the thrombin fac-
tor IIa, and factors Xa, IXa, XIa and XIIa. However, UH is asso-
ciated with a number of adverse events, such as thrombocytope-
nia. More recently, alternatives such as low molecular weight hep-
arin (LMWH), a derivative of UH, have been proposed. LMWH
acts in the same way as UH, but its low molecular weight frag-
ments reduce the binding to other cells and proteins (and it also
has a major affinity to factor Xa) (Hirsh 2004). These drugs have
potential as effective prophylactic interventions for trauma, al-
though there is concern due to the associated increased risk of
bleeding (Geerts 1996; Haentjens 1996; Knudson 1996; Cohn
1999). Other methods of thromboprophylaxis, such as anticoag-
ulants (warfarin) or antiplatelets (aspirin), seem less practical for
use in critically ill patients, because of their delayed action and
oral presentation. Pentassacharides (a new class of synthetic selec-
tive factor Xa inhibitor, with parenteral presentation which does
not bind to platelets, other cells or proteins) have been studied as
prophylaxis in surgical orthopedic patients and have been shown
to be as effective as UH and LMWH (Nijkeuter 2004).
How the intervention might work
Due to prolonged rest and coagulation abnormalities, trauma pa-
tients are at increased risk of thrombus formation. Thrombopro-
hylaxis, either mechanical or pharmacological, may decrease the
mortality and morbidity in trauma patients who survive beyond
the first day in hospital, by decreasing the risk of DVT and PE
in this population. A previous Cochrane review focusing on high-
risk patients indicated that combined methods (pharmacologic
and mechanical interventions) decreased the incidence of DVT
(Kakkos 2008). However, this systematic review did not examine
the effects in the subgroup of trauma patients.
Why it is important to do this review
Trauma patients are at an increased risk of VTE, and thrombopro-
phylaxis has the potential to be effective in this population. How-
ever, trauma patients are at an increased risk of bleeding, which is
one of the adverse events associated with pharmacological inter-
ventions. For some trauma patients with injured extremities, the
use of mechanical interventions (e.g. external mechanical com-
pression) is not feasible. A previous systematic review (Velmahos
2000) did not find evidence of effectiveness for either pharmaco-
logical or mechanical interventions. However, this systematic re-
view was conducted 10 years ago and most of the included studies
were of poor quality. Since then new trials have been conducted.
Although current guidelines (Rogers 2002; Geerts 2008) recom-
mend the use of thromboprophylaxis in trauma patients, there has
not been a comprehensive and updated systematic review since
the one published by Velmahos et al. Furthermore, there are still
uncertainties about the relative benefit of interventions for differ-
ent subgroups of trauma patients. Therefore it is necessary to con-
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duct a systematic review to establish whether the effect of different
thromboprophylaxis interventions varies according to the type of
trauma, location of the trauma, severity of trauma and type of
management (surgical or medical management).
O B J E C T I V E S
To assess the effects of thromboprophylaxis in trauma patients on
mortality and incidence of DVT and PE.
To compare the effects of different thromboprophylaxis interven-
tions and their effects according to the type of trauma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled clinical trials.
Types of participants
People of any age with major trauma defined by one or more of
the following criteria;
• physiological: penetrating or blunt trauma with more than
two organs and unstable vital signs,
• anatomical: patients with an Injury Severity Score (ISS)
higher than 9,
• mechanism: patients who are involved in a ’high energy’
event with a risk for severe injury despite stable or normal vital
signs.
We excluded trials that only recruited outpatients, trials than re-
cruited patients with hip fractures only, or patients with only acute
spinal injuries.
Types of interventions
We included trials investigating any of the following interventions;
1. Unfractionated heparin (UH),
2. Low weight molecular heparin (LWMH),
3. Mechanical methods: graded compression stocking, and
sequential compression devices,
4. Oral anticoagulants (e.g. warfarin),
5. Antiplatelet drugs (e.g. aspirin),
6. Pentassacharides,
7. Pulmonary embolism prophylaxis (e.g. inferior vena cava
filter (IVCF)).
We compared the effects of any intervention with placebo, and
any two interventions (e.g. LMWH versus UH) or combination
of interventions (UH plus mechanical methods versus UH).
Types of outcome measures
Primary outcomes
The primary outcome was mortality.
Secondary outcomes
The secondary outcomes were the incidence of DVT, PE and
adverse events, such as:
• bleeding (major and minor);
• whether the adverse event (bleeding of the injured site,
intracranial bleeding, gastrointestinal bleeding, epistaxis, etc.)
required transfusion or any procedure to control it;
• and other adverse events as defined by the trial authors.
Search methods for identification of studies
Wedid not restrict searches by date, language or publication status.
Electronic searches
We searched the following electronic databases:
• Cochrane Injuries Group’s Specialised Register (searched
April 30 2009);
• Cochrane Central Register of Controlled Trials 2009, issue
2 (The Cochrane Library);
• MEDLINE (Ovid) 1950 to April (week 3) 2009;
• EMBASE (Ovid) 1980 to (week 17) April 2009;
• PubMed [http://www.ncbi.nlm.nih.gov/sites/entrez]
(searched 29 April 2009);
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) (1970 to April 2009);
• ISI Web of Science: Conference Proceedings Citation
Index-Science (CPCI-S) (1990 to April 2009).
Search strategies are listed in full in Appendix 1.
Searching other resources
We searched the bibliographies of all included studies and other
relevant papers for further potentially eligible trials. We searched
the Internet using the Google (www.google.com) search engine
with selected terms from the strategy to identify any further un-
published or grey literature.
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Data collection and analysis
The Injuries Group Trials Search Co-ordinator ran the electronic
database searches, collated the search results, removed duplicates
then sent the remaining records to the authors for screening
Selection of studies
Four authors, in pairs (LB and CM, EF and RC), independently
examined titles, abstracts, and keywords of citations from elec-
tronic databases for eligibility. We obtained the full texts of all po-
tentially relevant records and two authors (EF and CM) indepen-
dently assessed whether each met the pre-defined inclusion crite-
ria. We resolved any disagreement through discussion with a third
author (PP).
Data extraction and management
Four authors, in pairs (LB and CM, EF and RC) extracted data
independently, using a standardized data extraction form. LB en-
tered the extracted information into Review Manager (RevMan
2008) for analysis. We extracted data on the following:
1. General Information: title, authors, source of publication,
country, published or not, language and year of publication.
2. Trial characteristics: study design and information that
meets the Cochrane Collaboration’s tool for assessing risk of bias.
3. Participants: sample size, inclusion criteria, exclusion
criteria, location of trauma (brain, chest, abdomen, pelvis,
extremity, polytrauma), severity of trauma (ISS, RTS, or
according to the scale used by the trialists), type of injury (blunt
or penetrating), and type of surgical procedure (non-operative or
surgical management).
4. Intervention: type and dose of thromboprophylaxis used,
type and dose of control or placebo used.
5. Outcomes: incidence of mortality, incidence of DVT
(symptomatic or asymptomatic) and diagnostic test used,
incidence of PE and diagnostic test used. Incidence of adverse
events as follows: any bleeding, major bleeding defined as use of
transfusion or any procedure to control bleeding (bleeding from
the injured site, gastrointestinal bleeding, brain bleeding,
epistaxis, etc.) and minor bleeding. Other outcomes recorded by
the authors.
6. Results: number of patients in each group, missing patients.
7. Subgroup characteristics: number of patients by localization
of trauma, by severity, by type (blunt or penetrating), by type of
management (surgical or non-surgical).
8. Other information: funding source.
Assessment of risk of bias in included studies
Four authors in pairs (LB and CM, EF and RC) assessed the risk of
bias of each included trial using the Cochrane Collaboration’s tool
for assessing risk of bias presented in Higgins 2008. We assessed
the following domains: sequence generation; allocation conceal-
ment; blinding; incomplete outcome data; and selective outcome
reporting. We completed risk of bias tables for each trial, incor-
porating a description of the trial’s performance against each do-
main and our overall judgment of the risk of bias for each entry
as follows: ’Yes’ for low risk of bias; ’No’ for high risk of bias, or
’Unclear’. We resolved disagreements by consulting a third author
(PP).
Measures of treatment effect
For dichotomous data we calculated risk ratios (RR) and 95%
confidence intervals (CIs). We also calculated number needed to
treat (NNT) and number needed to harm (NNH).
For continuous data we calculated the mean difference (MD) and
95% CIs when the same scale was used in a similar manner across
studies. If results for continuous outcomes were reported using
different scales or different versions of the same scale, we calculated
the standardised mean difference (SMD) and 95% CIs.
Dealing with missing data
We did not contact the trial authors for missing information.
Assessment of heterogeneity
We examined trial characteristics in terms of participants, inter-
ventions and outcomes for evidence of clinical heterogeneity. We
examined statistical heterogeneity by both the I2 statistic and Chi
2 test. The I2 statistic describes the percentage of total variation
across studies due to heterogeneity rather than chance. A value of
0% indicates no observed heterogeneity, and larger values show
increasing heterogeneity; substantial heterogeneity is considered
to exist when I2 is larger than 50%. For the Chi2 test, we used
a p value of less than 0.10 to indicate the presence of statistically
significant heterogeneity.
Assessment of reporting biases
We planned to investigate the presence of reporting (publication)
bias using funnel plots, however there were too few included trials
contributing data to each outcome to enable meaningful analysis.
Data synthesis
We judged that the trials were sufficiently homogenous, both clin-
ically and statistically, to pool the outcome data. Dichotomous
data were pooled using the Mantel-Haenszel fixed-effect method
and continuous data were pooled using the fixed-effect inverse-
variance method.
Because different effects were expected according to the interven-
tion, we performed data synthesis separately for each type (e.g.
UH, LWMH or mechanical devices).
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Subgroup analysis and investigation of heterogeneity
There were insufficient data to perform the following planned
subgroup analyses:
• type of trauma (blunt, penetrating);
• location of the trauma (brain, chest, abdominal, pelvis,
extremity or polytrauma);
• severity of trauma defined with ISS or other similar scores;
• management (surgical or medical management);
• diagnostic method.
Sensitivity analysis
We performed a sensitivity analysis to investigate whether the re-
sults were robust. We examined the effect of excluding certain
studies according to their risk of bias. We reported the data synthe-
sis for all the included studies and repeated the calculations after
excluding studies judged as having a high risk of bias for alloca-
tion concealment. We also examined the effect of using a different
effect measure (odds ratio) for the dichotomous outcomes.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The combined search strategy identified 2858 citations, of which
38 were judged to be potentially eligible based on title or abstract,
or both, and the full texts were obtained. After a full text review,
16 trials were judged to be eligible and were included in the review,
one was reported as an abstract.
Included studies
We included 3005 people of any age who had major trauma.
1898 people had blunt trauma and 225 people had penetrating
trauma. Four trials did not report the injury mechanism (Fuchs
2005; Ginzburg 2003; Knudson 1996; Yanar 2007). Most of the
studies reported the ISS. The average of the ISS reported by the
trials varies between 13 and 30. Five studies did not report the
ISS value. Six studies reported a specific management. 816 with
operative treatment and 173 with non operative treatment.
The Knudson 1994 All groups study was divided in four groups:
Knudson 1994 All groups, Knudson 1994 group I (UH vs SCDvs
Placebo), Knudson 1994 group II (UH vs Placebo) and Knudson
1994 group III (SCD vs Placebo).
Four trials compared a method of prophylaxis with no prophylaxis
(Dennis 1993; Fisher 1995; Knudson 1994 All groups; Velmahos
2005).
Two trials compared pharmacological methods (LMWH with
UH) (Cohn 1999; Geerts 1996).
Three trials compared mechanical methods (thigh calf sequential
compression device with a foot-calf pump) (Anglen 1998; Elliot
1999; Stannard 2001).
Five trials compared pharmacological with mechanical methods,
of which three compared LMWH with Intermittent Pneumatic
Compression (IPC) devices (Ginzburg 2003; Kurtoglu 2004;
Yanar 2007) and two compared UHwith Sequential Compression
Devices (SCD) (Knudson 1992; Knudson 1994 group I).
Four trials compared a combination of pharmacological and me-
chanical interventions. One trial allocated patients to three groups
to compare IPC, IPC plus LMWH and LMWH alone (Yanar
2007). The other three trials compared pharmacological plus
mechanical methods with pharmacological prophylactics (Fuchs
2005; Stannard 2006; Yanar 2007).
All 16 trials used doppler ultrasound (Duplex) to diagnose DVT.
The diagnosis was confirmed with venography in three trials (
Geerts 1996; Fuchs 2005; Fisher 1995), and by Duplex and MRI
venography in one trial (Stannard 2001).
Sixteen trials presented data on pulmonary embolism. PE was
diagnosed clinically in two trials (Anglen 1998; Fuchs 2005); by
a V/Q scan and pulmonary angiography in five trials (Knudson
1992; Knudson 1994 All groups; Knudson 1996; Geerts 1996;
Cohn 1999); by CT scan angiography on clinically suspected cases
in two trials (Kurtoglu 2004; Yanar 2007); by clinical suspicion
and autopsy in one trial (Elliot 1999); by angiography and autopsy
in two trials (Fisher 1995; Dennis 1993); by used ventilation/
perfusion scan (V/Q scan), angiography and CT scan angiography
in one trial (Ginzburg 2003); and byMRI angiography in one trial
(Stannard 2006). The method used in the remaining two trials
was not described (Velmahos 2005; Stannard 2001).
Further details of the individual trials are presented in the
Characteristics of included studies table.
Excluded studies
Of the trials excluded from our review three were not randomised (
Greenfiel 1997; Holzheimer 2004; Reilmann 1986), two included
only outpatients or elective surgery patients (Haas 2003; Wolf
1992), one involved hip fracture surgery patients (Breyer 1986)
and one did not measure any outcomes of interest to this review
(Murakami 2003).
Details are presented in the Characteristics of excluded studies.
Risk of bias in included studies
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Allocation
Eleven of the 16 studies had a low risk in the sequence generation
of the treatment groups, three of them had high risk of bias and
two were unclear.
In half of the studies included the allocation concealment was
unclear, four of the 16 had low risk in the allocation and the other
four studies had high risk of bias.
Blinding
Blinding was well conducted in seven of the 16 studies, in five
there was a high risk of bias and in four the data were insufficient
to establish the quality of blinding.
Incomplete outcome data
Six studies performed an intention to treat analysis, in nine there
was a high risk bias because outcome data were analysed in an
incomplete fashion, and just one of them did not allow us to
establish the risk.
Selective reporting
We were unable to obtain the protocols for any of the trials, there-
fore the reporting bias was unclear for all 16 trials.
Effects of interventions
All the collected material allowed us to perform 7 comparisons,
we made four comparisons as a sensitivity analysis. As established
in the protocol we compared any method of prophylaxis versus
no prophylaxis, between prophylaxis methods and combinations
of them. The most important are highlighted in this text section.
The detailed analysis can be seen in the Data and analyses section.
Prophylaxis versus no prophylaxis
Four trials involving 997 people compared the effect of any type
(mechanical and/or pharmacological) of prophylaxis versus no
prophylaxis. Prophylaxis reduced the risk of DVT in trauma pa-
tients (RR 0.52; 95% CI 0.32 to 0.84). There was no evidence of
statistical heterogeneity between trials (I2=12%; Chi2 P=0.333).
There was no evidence for an effect on PE (RR 0.65; 95% CI 0.29
to 1.43) or mortality (RR 0.59; 95% CI 0.20 to 1.70).
Three trials reported the effect on bleeding, no events were ob-
served in any trial.
Mechanical prophylaxis versus no prophylaxis
Six trials involving 811 people compared the effect of mechanical
prophylaxis with no prophylaxis.
Mechanical prophylaxis reduced the risk of DVT (RR 0.55; 95%
CI 0.34 to 0.90). There was no evidence of statistical heterogeneity
between trials (I2 = 22%, Chi2 P=0.28). There was no evidence
that mechanical prophylaxis reduced the risk of PE (RR 0.77; 95%
CI 0.36 to 1.66) or death (RR 0.74; 95% CI 0.27 to 2.04).
Four trials (507 patients) reported the effect on bleeding, no events
were observed in any trial.
Pharmacological prophylaxis versus mechanical
prophylaxis
Six trials involving 1033 people compared pharmacological pro-
phylaxis with mechanical prophylaxis.
Pharmacological prophylaxis was more effective than mechanical
methods at reducing the risk of DVT (RR 0.48; 95% CI 0.25 to
0.95). There was no evidence of heterogeneity between trials (I
2=0%, Chi2 P=0.56). There was no evidence for a difference in
effect on the risk of PE (RR 0.94; 95% CI 0.36 to 2.42) or death
(RR 1.50; 95% CI 0.44 to 5.16).
Five of the trials (953 patients) reported bleeding outcome data.
Pharmacological prophylaxis increased the risk of bleeding (RR
2.04; 95% CI 1.08 to 3.86) compared to mechanical methods.
There was no evidence of heterogeneity (I2=0%, Chi2 P=0.53).
Three trials (764 patients) distinguished betweenmajor andminor
bleeding. There was no evidence for a difference in effect on the
risk of major bleeding (RR 1.03; 95% CI 0.26 to 4.06). However,
pharmacological prophylaxis increased the risk of minor bleeding
(RR 2.37; 95% CI 1.13 to 4.98). There was no evidence for het-
erogeneity between trials (I2=0%; Chi2 P=0.64).
Low Molecular Weight Heparin versus
Unfractionated Heparin
Two trials involving 331 patients compared low molecular weight
heparin (LMWH) with unfractionated heparin (UH). LMWH
appeared to reduce the risk of DVT compared to UH (RR 0.68;
95% CI 0.50 to 0.94). There was no evidence for heterogeneity
between trials (I2 = 0%, Chi2 P=0.46).
There was no statistically significant difference in the risk of PE
between the two groups (RR 3.16; 95% CI 0.13 to 76.91) and
there were no deaths reported in either trial.
There was no statistically significant difference in the risk of bleed-
ing between LMWH and UH (RR 1.63; 95% CI 0.63 to 4.22).
Mechanical plus pharmacological prophylaxis versus
Pharmacological prophylaxis
Three trials involving 507 patients compared mechanical prophy-
laxis plus pharmacological prophylaxis with pharmacological pro-
phylaxis alone. Patients who received both mechanical and phar-
macological prophylaxis had a lower risk of DVT (RR 0.34; 95%
CI 0.19 to 0.60). However, there was evidence for statistical het-
erogeneity between trials (I2= 69%, Chi2 P=0.04).
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There was no evidence for a difference in effect on the risk of PE
(RR 0.32; 95% CI 0.05 to 2.01) or death (RR 0.50; 95% CI 0.05
to 5.30).
One trial assessed the effect on bleeding and found no difference
in the risk of bleeding between the two groups (RR 0.99; 95% CI
0.56 to 1.78).
Other comparisons
One study compared mechanical plus pharmacological prophy-
laxis versus mechanical prophylaxis (Yanar 2007) and did not find
difference. Also three trials compared thigh-calf versus calf-foot
methods (Anglen 1998; Elliot 1999; Stannard 2001) did not find
either statistical difference.
Sensitivity Analyses
The sensitivity analysis included only the studies that were consid-
ered at low risk of bias for allocation concealment. We made four
comparisons of the results, which showed a statistically significant
difference.
The comparisons of prophylaxis vs no prophylaxis andmechanical
methods vs no prophylaxis, could include only one study (Fisher
1995). It showed a tendency to be superior for prophylaxis, but
without reaching a statistically significant difference (RR 0.35;
95% CI 0.11 to 1.10).
When we compare LMWH vs UH, we could include just one
study (Geerts 1996) which showed strong evidence that LMWH
was superior for prevention of DVT (RR 0.57; 95% CI 0.34 to
0.94).
When we compare mechanical with pharmacological prophylaxis
we also could include just one study (Ginzburg 2003) but did not
show any significant difference (RR 0.17; 95% CI 0.02 to 1.41).
D I S C U S S I O N
Summary of main results
This systematic review gathers all the available evidence from all
randomised controlled trials which compare the use of pharma-
cological and mechanical thromboprophylaxis in patients with
severe trauma. We excluded trials that only recruited outpatients,
patients presenting only with hip fractures, acute spinal injuries
and low energy trauma.
Among trauma patients who did not receive any prophylaxis we
found that deep venous thrombosis (DVT) incidence was 8.72%
(37/424) diagnosed by Dupplex. The incidence of pulmonary
embolism (PE) was 3.3% (14/424) for PE diagnosed by VQ scan
or angiography or autopsy (Dennis 1993; Fisher 1995; Knudson
1994 All groups; Velmahos 2005).
We did not find evidence that thromboprophylaxis reduces the
primary outcome mortality or the secondary outcome PE for any
of the comparisons assessed.
However, we found some evidence of effective interventions for the
prevention of the secondary outcome DVT. Prophylaxis was more
effective than no prophylaxis, pharmacological prophylaxis than
mechanical prophylaxis, and LMWH than UH. However, these
results were based on a few small trials with relatively few events
and poor methodology quality. We also found some evidence that
patients who received pharmacological thromboprophylaxis have
a higher risk of minor bleeding compared to patients who received
mechanical therapy. At the moment there is no RCT published
for major trauma with dabigatran or rivaroxiban.
Although the strength of the evidence found in this review was not
strong our findings are similar to previous reviews conducted in
different but related conditions (Surgical non traumatized, cancer,
hip fractures) (Wille-Jørgensen 2008; Bani-Hani 2011; Handoll
2008). The present review strengthens the clinical practice guide-
lines recommendations from Eastern Association for the Surgery
of Trauma (Rogers 2002) and American College of Chest Physi-
cians (Kahn 2012; Geerts 2008), providing further evidence for
thromboprophylaxis in patients with severe trauma.
Overall completeness and applicability of
evidence
We did not find enough studies to allow any comparison between
pharmacological prophylaxis against placebo. There are also not
enough studies which evaluate specific pharmacological interven-
tions (UW or LMWH) vs specific mechanical therapies (SCD or
AVI).
Quality of the evidence
The quality of evidence was low as only one of the four studies
included for the main comparison (prophylaxis versus no prophy-
laxis) had low risk of selection bias as judged by the allocation
concealment process. Also the external validity could be threat-
ened because of sponsorship by mechanical devices manufacturers
(Velmahos 2005).
Potential biases in the review process
Potential biases in the review process are mainly defined by an
impossibility to analyse a study due to an abstract inclusion in the
meta-analysis (Yanar 2007). We tried to minimize selection bias
by working, collecting and analysing all studies in pairs (LB-CM
and EF-RC). All differences where resolved by consensus and also
through the input of PP.
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Agreements and disagreements with other
studies or reviews
Previous meta-analyses (Velmahos 2000) have shown no evidence
that low-dose unfractionated heparin, mechanical prophylaxis, or
low-molecular weight heparin are more effective than no prophy-
laxis or among each other. In addition, unlike ours, this systematic
review included observational studies which provide less reliable
evidence of effectiveness for medical interventions.
A recent systematic review (Smith 2011) with severe skeletal
trauma as its main inclusion criteria suggested that low molecu-
lar weight heparin (LMWH) may be superior to low dose hep-
arin (LDH), and that LMWH should be used in addition to me-
chanical prophylaxis measures in patients following major skeletal
trauma for the prevention of thromboembolic events, this findings
do not differ from ours. The analysed studies were included in
this meta-analysis, the difference between these systematic reviews
were that they just include major skeletal trauma.
Bleedingwas not analysed as an outcome in previousmeta-analysis
and not all of the trials considered bleeding as an outcome.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although the strength of the evidence included in this review was
not high, taking into account existing information from other re-
lated conditions such as surgery, we believe that the use throm-
boprophylaxis for preventing DVT in severe trauma patients is
recommended.
Implications for research
Adequately powered trials should be conducted to compare dif-
ferent thromboprophylaxis strategies. Also we would recommend
that future RCTs should have a more uniform and definedmethod
of diagnosing both DVT and PE so as to measure the true effect
thromboprophylaxis.
In addition to mortality, DVT and PE, future trials should assess
the following outcomes which have important clinical implica-
tions:
1. Adverse events of pharmacological prophylaxis such as bleeding.
2. Post-discharge consequences of DVT in postraumatic patients
including postphlebitic syndrome, chronic DVT or chronic PE.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anglen 1998
Methods Randomized control trial
Participants 117 participants randomised: 49 for sequential compression device (SCD) and 68 for
Plantar venous pneumatic compression (P )
Gender: SCD M 38 F 30 P M 27 F 22
Mean age: SCD 38 (17-82) P 41 (18-83).
Inclusion Criteria All Adult trauma with fracture of the pelvic ring, acetabulum or femur
Exclusion Criteria: Inabilty of give informed consent, preexisting thrombosis, active
anticoagulation,inability to use the devices
Type of Injury All were blunt trauma
Location of trauma: Spine: Not reported Head: Not reported Face: Not reported Chest:
Not reported Abdomen: Not reported Pelvis: SCD 26 P 24 Extremity: 36 to 23 PolI-
trauma (more than one): 42 to 30
Severity of trauma (ISS, RTS) not reported:
Type of management (Operatory, Non operatory, both or not reported): Operatory
Interventions thigh-calf sequential-compression device (Kendall SCD; Kendall, Mansfield, Mas-
sachusetts)
PlexiPulse foot pumps (Kinetic Concepts, San Antonio, Texas)
Outcomes Diagnostic method for DVT: Doppler ultrasonography




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No (Medical record number).
Allocation concealment (selection bias) High risk No (Medical record number).
Blinding (performance bias and detection
bias)
All outcomes
Low risk The scans were read by radiology in a blinded fashion.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Unclear risk Protocol not known.
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Cohn 1999
Methods Randomized control trial
Participants 66 participants randomised (32 for low dose unfractionated heparin (UH) and34 for
LMWH)
Gender: Not reported
Mean age: 44±17 years for UH to 38±15 years for LMWH
Inclusion Criteria: Any trauma patients with at least one of the following risk factors:
Age > 45, expectation of > 2 days bedrest, history of DVT or PE, coma (CGS <7), spine
cord injury, pelvic fracture,lower extremity fractures, and repair of mayor extremity vein,
complex wound of lower extremity, femoral venous catheter
Exclusion Criteria: Age < 18, sever blunt head injury, bleeding injuries no accessible to
haemostatic control , active bleedingdisorder, cardiovascular instability, nursingmothers,
heparin, warfarin or heparinoids within 7 days of trauma, allergy of heparin, bisulphite
or fish, history of protein C deficiency, history of heparin associated thrombocytopenia,
malignant hypertension blood pressures over 250 systolic and 130 diastolic, liver failure
with encephalopathy, renal failure or failure to obtain informed consent
Type of Injury : UH Blunt: 31 Penetrating: 1 to :LMWH. Blunt 32 Penetrating:2
Location of trauma: Not reported.
Severity of trauma ISS mean: UH ISS mean13+/-14 to LMWH ISS mean 10 +/- 5
Type of management (Operatory , Non operatory, both or not reported): Not reported
Interventions UH 5000 U SC BID
LMWH 30 mg SC BID
Outcomes Diagnostic method for DVT: Doppler ultrasonography
Diagnostic method for PE: Clinically, V/Q and angiograms .
Any bleeding? Yes.
Major Bleeding (need of transfusion, any procedure to control bleeding)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated schedule.
Allocation concealment (selection bias) Low risk Central allocation (pharmacy-controlled randomizations).
Blinding (performance bias and detection
bias)
All outcomes
High risk They don´ t say if the radiologist were blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk 104 patient were randomised but at the end just 66 patient
were analysed. They don´ t specify what happen with the
other 42 patients
Selective reporting (reporting bias) Unclear risk Protocol not known.
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Dennis 1993
Methods Randomized clinical trial
Participants 395 participants randomised (281 for sequential compression device or low dose unfrac-
tionated heparin and 114 for no prophylaxis)
Gender: Not reported
Mean age: 28.6 years for prophylaxis to 27.4 years for no prophylaxis
Inclusion Criteria: Any trauma
Exclusion Criteria: Less than 18 years or ISS of 9 or below.
Type of Injury (blunt , penetrated, both or not reported): Blunt: 320 Penetrating: 75.
Prophylaxis: Blunt: 233 Penetrating: 48. No prophylaxis:Blunt: 87 Penetrating: 27
Location of trauma: Spine: 39 to11 Head: 74 to 18 Face: Not reported Chest: 81 to 37
Abdomen: 68 to 24 Pelvis: Not reported Extremity: 137 to 51 PolItrauma (more than
one): Not reported
Severity of trauma (ISS, RTS) or not reported: ISS mean: Prophylaxis: 21.1 No prophy-
laxis: 20.5
Type of management (Operatory , Non operatory, both or not reported): Not reported
Interventions Prophylactic method: Full length lower extremity sequential compression device (SCD)
or those who have fractures or extensive soft tissue injuries of the lower extremity and
in cases where SCD were not available were given low dose of subcutaneous heparin at
a dose of 5000 units BID
No prophylactic method.
Outcomes Diagnostic method for DVT: Doppler ultrasonography
Diagnostic method for PE: Authopsy or Pulmonary angiography.
Any bleeding ? No.
Major Bleeding (need of transfusion, any procedure to control bleeding)
Minor Bleeding (no need none of the above)
Notes Less than 20% couldn’t perform the duplex because of the extremity injuries. 67 where
changed to prophylaxis group and analysed in the No prophylaxis group (Intervention
B)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk They were randomised, but they don´ t say how.
Allocation concealment (selection bias) Unclear risk They didn’t describe how allocate.
Blinding (performance bias and detection
bias)
All outcomes
High risk Incomplete information to establish whether the vascular
technician or attending vascular surgeon were blinded37%
of the 181 patients in the control group were switched from
no prophylaxis to a SCD at the discretion of the attending
surgeon who felt the risk of DVT and PE was too high
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Dennis 1993 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Per protocol analysis.
Selective reporting (reporting bias) Unclear risk All the outcomes were reported. (Protocol not known)
Elliot 1999
Methods Randomized control trial
Participants 149 participants randomised (74 for sequential compression device (Calf thigh device)
75 for sequential compression device (Plantar venous pneumatic compression)
Gender: Calf thigh device male 49 / female 25 Plantar venous pneumatic compression
male 51 / female 24
Mean age: 33.9 years for Calf thigh device to 30.2 years for Plantar venous pneumatic
compression
Inclusion Criteria: more than 13 years old and who had recent (within 24 hours) severe
head injuries (Glasgow Coma Scale score < 9) and/or major trauma and were expected
to be bedridden for more than 72 hours
Exclusion Criteria: Patients with external fixation devices or casts that precluded the use
of calf-thigh sequential pneumatic compression devices on either or both legs, patients
who were not expected to live more than 24 hours, and patients whose injuries occurred
more than 24 hours before admission
Type of Injury (blunt, penetrated, both or not reported): Blunt: 137 Penetrating: 12.Calf
thigh device Blunt: 68 Penetrating:6. Plantar venous pneumatic compression:Blunt: 69
Penetrating: 6
Location of trauma: Spine: Not reported Head: 62 to 61 Face: 23 to 14 Chest: 39 to 44
Abdomen: 17 to 22 Pelvis: Not reported Extremity: 10 to 10 Polytrauma (more than
one): Not reported
Severity of trauma (ISS, RTS) or not reported: ISS mean: Calf thigh device: 31.0 Plantar
venous pneumatic compression: 30.2
Type ofmanagement (Operatory,Non operatory, both or not reported): Calf thigh device
Operatory 12/Non operatory 62 Plantar venous pneumatic compression Operatory 10
/Non operatory 65
Interventions The calf-thigh sequential pneumatic compression devices consisted of four calf and two
thigh plastic chambers that inflate sequentially to a pressure of 45 mm Hg. The calf
chambers inflated sequentially from the ankle to the knee at 5-second intervals (as rec-
ommended by the manufacturer). The two thigh chambers then inflate sequentially in
a proximal direction. All chambers remain inflated for 5 seconds, then deflate simulta-
neously
The PlexipulseR has a single chamber that inflates for 2 seconds and cycles every 20
seconds. The chamber pressure was set to 160 mm Hg (as recommended by the manu-
facturer)
Outcomes Diagnostic method for DVT: Doppler ultrasonography
Diagnostic method for PE: No
Any bleeding ? Yes
Major Bleeding (need of transfusion, any procedure to control bleeding)
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Elliot 1999 (Continued)
Minor Bleeding (no need none of the above)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned by computer.
Allocation concealment (selection bias) Low risk Individual prophylaxis assignments were written on cards
and placed in sealed opaque envelopes with only the order
of assignment and stratification displayed
Blinding (performance bias and detection
bias)
All outcomes
Low risk They removed the calf-thigh sequential pneumatic compres-
sion devices or plantar venous intermittent pneumatic com-
pression devices from the patient and the patient’s room to
maintain an assessment that was blinded to the method of
venous thromboembolism prophylaxis
Incomplete outcome data (attrition bias)
All outcomes
Low risk 149 patients compose the intent to treat group.
Selective reporting (reporting bias) Unclear risk All the outcomes were reported. (Protocol not known)
Fisher 1995
Methods Randomized clinical Trial
Participants 304 participants randomised:145 for Pneumatico sequential leg compression devices
(PSLCD) and 159 for no prophylaxis
Gender: Not reported
Mean age: Not reported
Inclusion Criteria: Pelvic, acetabular, femoral neck, intertrochanteric or subtrochanteric
fractures
Exclusion Criteria: Abnormal coagulation profile, current or recent use of an antiplaquet
or anticoagulant medication, malignancy, severe liver disease, skin ulceration or large
open wound on lower extremity, objective evidence of DVT, severe multi-trauma in
which participation of another trauma service took precedence over the study protocol
Type of Injury All were blunt :PSLCD: Blunt: 145 No prophylaxis:Blunt: 154
Location of trauma: Pelvis:PSLCD 35 to No prophylaxis: 38 Extremity (hip fractures):
PSLCD 110 to No prophylaxis: 121
Severity of trauma: ISS mean: Not reported
Type of management : Operatory.
Interventions PSLCD: Portable controller with a pair of thigh length sleeves. Each sleeve contains
six chambers, four calf and two thigh. Sleevs were sequentially inflated to pressures of
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Fisher 1995 (Continued)
45 mm Hg at the ankle, 35-40 mm Hg at the calf, and 25 mm mg at the thigh.The
compression cycle is 71 sec, with each compression lasting 11 sec
No prophylactic method.
Outcomes Diagnostic method forDVT:Doppler ultrasonography. Equivocal or positive tests, when
indicated, were followed by venograms or autopsy
Diagnostic method for PE: VQ scan, angiography or autopsy
Any bleeding ? No.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization was by sealed enveloped and balanced in
blocks of 20
Allocation concealment (selection bias) Low risk Sealed envelopes.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Diagnostic test were assessed by a blinding radiologist, vas-
cular surgeon or nuclear medicine specialist
Incomplete outcome data (attrition bias)
All outcomes
High risk Reason for missing outcome data likely to be related to true
outcome, with either imbalance in numbers or reasons for
missing data across intervention groups
Selective reporting (reporting bias) Unclear risk All the outcomes were reported. (Protocol not known)
Fuchs 2005
Methods Randomized clinical trial
Participants 227 participants randomised (111 Arthroflow plus unfractioned heparin and 116 for
Unfractioned Heparin)
Gender: Arthroflow plus unfractioned heparin M 57 F 54 Unfractioned Heparin M74
F 42
Mean age: 47.1 (19.7) years for Arthroflow plus unfractioned heparin to 71.9 (19.5)
years forUnfractioned Heparin
Inclusion Criteria: Above 18 and below 80 years. Bony or ligamentous trauma of spine,
pelvis or extremities
Exclusion Criteria: Polytrauma, decompensated coronary heart disease, advance periph-
eral arterial occlusion, severe liver failure, haemorraghic diathesis, stroke, pregnancy,
malignant neoplasty, arthritis and arthrodesis of the lower limb, acute thrombosis or
thrombophlebitis, pulmonary embolism, paraplegia, chronic muscular dystrophy, lack
of compliance
Type of Injury (blunt , penetrated, both or not reported): Not reported
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Fuchs 2005 (Continued)
Location of trauma: Spine: 40 to 30 Head: Pelvis: 27 to 20 extremities 44 to 66
Severity of trauma (ISS, RTS) or not reported: No reported
Type of management (Operatory , Non operatory, both or not reported): Not reported
Interventions Arthroflow plus UH: UH 5000 ui TID and mobilization of the extremity for 30 min
TID
UH 5000 ui TID
Outcomes Diagnostic method for DVT: Doppler ultrasonography and plethysmography as screen-
ing. Confirmed diagnosis by Venography
Diagnostic method for PE: Clinically
Any bleeding ? Not reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned by computer.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Evaluated by blind radiologist.
Incomplete outcome data (attrition bias)
All outcomes
High risk Patients with trauma to the ankle had to be excluded from
to the arthroflow group
Selective reporting (reporting bias) Unclear risk All the outcomes were reported. (Protocol not known).
Geerts 1996
Methods Randomized clinical trial
Participants 265 participants randomised: 136 for low dose unfractionated heparin (LDUH) and
129 for LMWH
Gender: LDUH male 99 / female 37 LMWH male 93 / female 36
Mean age: LDUH 37.0± 16.5 and LMWH 39.1 ± 16.8
Inclusion Criteria: Any trauma in adults.
Exclusion Criteria: ISS below 9. Survival below 7 days. Hospital stay below 7 days.
Intracranial bleeding by CT. Uncontrolled bleeding after 36 hours of injury. Systemic
coagulopathy (PT more 3segs above control or platelets less than 50,000). Need of
therapeutic anticoagulation. Contrast allergy for venography. Renal failure. Pregnant.
Don´ t achieve venous access because amputation or major foot injury
Type of Injury Blunt trauma
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Geerts 1996 (Continued)
Location of trauma: Spine: 24 to 16 Head: 6 to 7 Face: Not reported Chest:Not reported
Abdomen: Not reported Pelvis: 25 to 23 Extremity: 75 to 69 Polytrauma (more than
one): Not reported
Severity of trauma: ISS mean: LDUH 22.7 ± 9 LMWH 23.1± 8
Type of management Operatory 119 to 107 non operatory 17 to 22
Interventions UH 5000 ui every 12 hours (0,3 ml preloaded syringes), 36 hours after the injury and
continued by 14 days. Witheld single preoperative dose and resumed dose after the
surgery
LMWH (Enoxaparin) 30 mg every 12 hours (0,3 ml preloaded syringes), 36 hours after
the injury and continued by 14 days. Witheld single preoperative dose and resumed dose
after the surgery
Outcomes Diagnostic method for DVT:Clinical surveillance, Clinical suspect diagnosis with US-
doppler and confirmation with Venography. If not (complete asymptomatic), Control
Venography days 10 to 14 after injury
Diagnostic method for PE: Clinical suspect with ventilation-perfusion scanning. Any
doubt will be confirmed with pulmonary angiography, venous ultrasonography or con-
trast venography or combinations of these
Any bleeding ? yes
Major Bleeding (need of transfusion, any procedure to control bleeding)
Minor Bleeding (no need none of the above)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned by a computer.
Allocation concealment (selection bias) Low risk Blinded fashion with preloaded syringes.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Imaging studies and episodes of bleeding were adjudicated
by a panel of experts who were unaware of the clinical data
Incomplete outcome data (attrition bias)
All outcomes
Low risk Without losses.
Selective reporting (reporting bias) Unclear risk Protocol not known.
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Ginzburg 2003
Methods Randomized clinical trial
Participants 442 participants randomised: 218 for LMWH and 224 for Intermitent Pneumatic Com-
pression (IPC).
Gender: 160 male for LMWH to 167 male for IPC
Mean age: 42 years forLMWH to 41 years for IPC.
Inclusion Criteria: Above 18 yeas old. ISS above 9. At least one leg and one arm available
for the IPC. Don’t need anticoagulation. Had no contraindication for LMWH
Exclusion Criteria: Under 18 years. ISS under 9. Unlikely to survive or remain in hospital
at least 7 days. Acute renal failure (creatinine above 3.4 mg/dL). Pregnant women.
Unable to undergo bilateral duplex. Morbid obesity (>25kg/m2). Contraindication of
coagulation: intracranial bleeding of uncontrolled bleeding from other sites for more
than 24 hours after admission. Coaugulopathy (PT> 3s/ control or plat < 50.000)
Type of Injury: Not reported.
Location of trauma: Spine: 18 to 15 Head: 41 to 60 Face: 11 to 11 Chest: 80 to 92
Abdomen: 53 to 63 Pelvis: 35 to 44 Extremity: 174 to 136 PolItrauma (more than one)
: Not reported
Severity of trauma (ISS, RTS) or not reported: Moderately (ISS 9-19): 294.Severe (ISS
>20):148
Moderate: ISS mean: LMWH: 12.4 (3.8) to IPC: 12.7 (3.9). Severe: ISSmean: LMWH:
25.3 (4.8) to IPC 25.9 (5.8). All ISS mean: ISS mean: LMWH: 16.7 (7.3) to IPC: 17.
1 (6.8)
Type of management: Not reported
Interventions LMWH (Enoxaparin): 30 mg SC BID. Begining 24h after trauma. Witheld 12h before
surgery and resumed 12h after.Two doses missed
IPC (Calf garment)(Huntleigh Flowtron,Manalapan, New Jersey,USA) placed both legs
inflated alternately to 40 mmHg every 60 s cycle. First cycle inflated 12 s and deflated
48s. Second cycle 30 s inflated and 30 s deflated. Tolerated for up to 8 h
Outcomes Diagnostic method for DVT: Doppler ultrasonography
Diagnostic method for PE: Clinically PE or CT scan or angiography or ventilation/
perfusion scan
Any bleeding ? Yes.
Major Bleeding (need of transfusion, any procedure to control bleeding)
Minor Bleeding (no need none of the above)
Notes The primary endpoint, the development of significant thromboembolic complications
while in hospital, served as the basis for the calculation of sample size. The protocol was
designed to consider all randomised and compliant patients in the analysis. The risk of
proximal DVT and pulmonary embolism in this study population was projected to be
around 10 per cent in the enoxaparin group on the basis of reports from similar trials8.
Enrolment of a total of 900 patients (450 in each arm) would be needed to allow the
confident detection of a clinically significant 30 per cent difference in treatment efficacy
between enoxaparin and IPC (power 80 per cent, one-sided significance 0·050) with an
anticipated non-compliance (drop out) rate of 5 per cent. This population size was based
on an expected incidence of DVT or pulmonary embolism of 20 per cent. However, at
planned interim analysis (442 patients), it was realized that the incidence was only 2·0
per cent. Based on this analysis, the decision was made to cease enrolment of subjects
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Ginzburg 2003 (Continued)
because a tenfold increase in patient numbers would have been needed to reach sig-
nificance. Because this protocol was designed to test equivalence and because LMWH
has been recognized as a standard of thromboprophylaxis, use of a one-tailed test was
justified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random.
Allocation concealment (selection bias) Low risk Investigators were blinded to treatment assignment before
randomisation
Blinding (performance bias and detection
bias)
All outcomes
High risk Single technician performed all scans. He was not blind.
Also all patients were assessed daily by the investigators.
Which means that investigators could see the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk Of the 442 randomised subjects 44 (15 in the IPC group
and 29 in the LMWH
group) were excluded from analysis because of compliance
issues
Selective reporting (reporting bias) Unclear risk Protocol not known.
Knudson 1992
Methods Randomized clinical trial
Participants 113 participants randomised (37 for low dose unfractionated heparin (LDUH) and 76
for Sequential pneumatic compression boots and elastic stockings (SCD and TED))
Gender: Not reported.
Mean age: 37.7 ± 15.8 years for LDUH to 37.8 ± 19.4 years for SCD and TED
Inclusion Criteria: Adults traumatized patients.
Exclusion Criteria: Pediatric trauma patients (below 17 years), pregnant trauma patients,
minor injuries, hospitalisation less than 48 hours,
Type of Injury: Blunt: 91 Penetrating: 11.
Location of trauma: Spine and Pelvis: 7 to 22 Head: 12 to 24 Face: Not reported Chest:
18 to 22 Abdomen: 13 to 23 Extremity: 27 to 30 PolItrauma (more than one): Not
reported
Severity of trauma (ISS, RTS) or not reported: ISS mean: LDUH: 15.9 ± 7.9 SCD and
TED: 18.5 ± 11.8
Type of management: Not reported.
Interventions Low Dose Unfractioned Heparin: 5000 ui SC BID.
Sequential pneumatic compression boots and elastic stockings (SCD and TED)
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Knudson 1992 (Continued)
Outcomes Diagnostic method for DVT: Real time B mode ultrasound / 5 days for tree weeks until
discharge
Diagnostic method for PE: V/Q radionuclide and or pulmonary angiograms
Any bleeding ? No.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Even and odds.
Allocation concealment (selection bias) High risk Alternative.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk They didn’t say whether the technologist or radiologist were
blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Per protocol analysis.
Knudson 1994 All groups
Methods Randomized clinical trial
Participants 251 participants randomised in three groups:
Gender: Male 200/ Female 51
Mean age: 38 years.
Inclusion Criteria:
Group I: Any trauma patients seriously injured. With duplex scan negative the first day
before the randomising. Who could receive either of the two methods of prophylaxis
Group II: Any trauma patients seriously injured. With duplex scan negative the first day
before the randomising. Who could not wear bilateral devices
Group III: Any trauma patients seriously injured. With duplex scan negative the first
day before the randomising. Who had any contraindication to receive heparin
Exclusion Criteria:
Group I: Younger than 18 year old, pregnant and prisoners.
Group II: Younger than 18 year old, pregnant and prisoners.
Group III: Younger than 18 year old, pregnant and prisoners.
Type of Injury: 140 blunt, 111 penetrating ( 65 stab wounds and 46 firearm)
Location of trauma: Not reported.
Severity of trauma: Not reported
Type of management: Not reported
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Knudson 1994 All groups (Continued)
Interventions Group I: Low Dose Unfractioned Heparin: 5000 ui SC BID or Sequential pneumatic
compression boots and elastic stockings (SCD and TED) vs Control
Group II: Low Dose Unfractioned Heparin: 5000 ui SC BID vs Control
Group III: Sequential pneumatic compression boots and elastic stockings (SCD and
TED) vs Control
Outcomes Diagnostic method for DVT: Dupplex.
Diagnostic method for PE: V/Q and angiograms
Any bleeding ? No.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random drawing.
Allocation concealment (selection bias) High risk Allocated by the possibility to wear the devices or to receive
heparin
Blinding (performance bias and detection
bias)
All outcomes
High risk It is not reported if the technologist or radiologist were
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 145 missing patients.
Selective reporting (reporting bias) Unclear risk Protocol not known.
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Knudson 1994 group II
Methods Randomized clinical trial
Participants 251 participants randomised in three groups:
Gender: Male 200/ Female 51
Mean age: 38 years.
Inclusion Criteria:
Group I: Any trauma patients seriously injured. With duplex scan negative the first day
before the randomising. Who could receive either of the two methods of prophylaxis
Group II: Any trauma patients seriously injured. With duplex scan negative the first day
before the randomising. Who could not wear bilateral devices
Group III: Any trauma patients seriously injured. With duplex scan negative the first
day before the randomising. Who had any contraindication to receive heparin
Exclusion Criteria:
Group I: Younger than 18 year old, pregnant and prisoners.
Group II: Younger than 18 year old, pregnant and prisoners.
Group III: Younger than 18 year old, pregnant and prisoners.
Type of Injury: 140 blunt, 111 penetrating ( 65 stab wounds and 46 firearm)
Location of trauma: Not reported.
Severity of trauma: Not reported
Type of management: Not reported
Interventions Group I: Low Dose Unfractioned Heparin: 5000 u SC BID or Sequential pneumatic
compression boots and elastic stockings (SCD and TED) vs Control
Group II: Low Dose Unfractioned Heparin: 5000 u SC BID vs Control
Group III: Sequential pneumatic compression boots and elastic stockings (SCD and
TED) vs Control
Outcomes Diagnostic method for DVT: Dupplex.
Diagnostic method for PE: V/Q and angiograms
Any bleeding ? No.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random drawing.
Allocation concealment (selection bias) High risk Allocated by the possibility to wear the devices or to receive
heparin
Blinding (performance bias and detection
bias)
All outcomes
High risk They didn´ t say weather the technologist or radiologist were
blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 145 missing patients.
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Knudson 1994 group II (Continued)
Selective reporting (reporting bias) Unclear risk Protocol not known.
Knudson 1994 group III
Methods Randomized clinical trial
Participants 251 participants randomised in three groups:
Gender: Male 200/ Female 51
Mean age: 38 years.
Inclusion Criteria:
Group I: Any trauma patients seriously injured. With duplex scan negative the first day
before the randomising. Who could receive either of the two methods of prophylaxis
Group II: Any trauma patients seriously injured. With duplex scan negative the first day
before the randomising. Who could not wear bilateral devices
Group III: Any trauma patients seriously injured. With duplex scan negative the first
day before the randomising. Who had any contraindication to receive heparin
Exclusion Criteria:
Group I: Younger than 18 year old, pregnant and prisoners.
Group II: Younger than 18 year old, pregnant and prisoners.
Group III: Younger than 18 year old, pregnant and prisoners.
Type of Injury: 140 blunt, 111 penetrating ( 65 stab wounds and 46 firearm)
Location of trauma: Not reported.
Severity of trauma: Not reported
Type of management: Not reported
Interventions Group I: Low Dose Unfractioned Heparin: 5000 u SC BID or Sequential pneumatic
compression boots and elastic stockings (SCD and TED) vs Control
Group II: Low Dose Unfractioned Heparin: 5000 u SC BID vs Control
Group III: Sequential pneumatic compression boots and elastic stockings (SCD and
TED) vs Control
Outcomes Diagnostic method for DVT: Dupplex.
Diagnostic method for PE: V/Q and angiograms
Any bleeding ? No.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random drawing.
Allocation concealment (selection bias) High risk Allocated by the possibility to wear the devices or to receive
heparin
26Thromboprophylaxis for trauma patients (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Knudson 1994 group III (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk They didn’t say weather the technologist or radiologist were
blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 145 missing patients.
Selective reporting (reporting bias) Unclear risk Protocol not known.
Knudson 1996
Methods Randomized clinical trial
Participants 202 participants randomised (120 for low molecular weight heparin -LMWH- and 82
for SCD or arteriovenous impulse (AVI) device )
Gender: Not reported
Mean age: 39 years for LMWH to 38 years for SCD and AVI.
Inclusion Criteria: Injury Severity Score (ISS) of > 10 or Abbreviated Injury Scale score
greater than or equal to 3 in any category; head injury with Glasgow Coma Scale score
less than or equal to 8; unstable spine fracture without neurologic deficit; spine fracture
with deficit; major pelvic fracture (Tile Class B or C); fracture of the lower extremity
above the ankle; previous history of DVT; acute venous injury; or age >50 years
Exclusion Criteria: the presence of DVT on admission, patients younger than 18 years
of age, pregnant patients, prisoners, patients who could not be randomised within the
first 24 hours of hospitalisation, and patients who refused consent. included discharge
or transfer from the hospital before 5 days post injury, bleeding disorders possibly asso-
ciated with the use of LMWH, noncompliance with the assigned prophylactic measure,
or evidence of DVT on duplex examination or PE by ventilation-perfusion scan or an-
giography
Type of Injury Blunt trauma and penetrating trauma.
Location of trauma: Not reported.
Severity of trauma ISS mean: LMWH 14 SCD and AVI. 16
Type of management (Operatory , Non operatory, both or not reported): Not reported
Interventions LMWH (enoxaparin sodium, Rhone Poulenc Rorer Pharmaceuticals Inc., Collegeville,
Pa) 30 mg subcutaneously every 12 hours
Sequential gradient pneumatic compression (SCD) or arteriovenous impulse (AVI) de-
vice
Outcomes Diagnostic method for DVT: venous duplex
Diagnostic method for PE: Clinical observation, Arterial blood gases and oxygen satura-
tion , three ventilation-perfusion scans and two pulmonary angiograms were performed
for unexplained respiratory distress or hypoxic episodes
Any bleeding ? No.
Major Bleeding (need of transfusion, any procedure to control bleeding)
Minor Bleeding (no need none of the above)
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Notes From 372 patients were assigned to a Heparin or a No-Heparin group, depending upon
the presence of injuries that would preclude the use of heparin in the early period after
injury. Just 202 patient were randomised in the heparin group to receive heparin or SCD
or AVI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random.
Allocation concealment (selection bias) Unclear risk Insufficient information.
Blinding (performance bias and detection
bias)
All outcomes
High risk Venous duplex examinations were performed by vascular
technician with over 10 years of experience. But the article
didn’t say whether the vascular technician were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk The heparin group that were randomised did not have any
losses
Selective reporting (reporting bias) Unclear risk Protocol not known.
Kurtoglu 2004
Methods Randomized clinical trial
Participants 120 participants randomised (60 for intermittent pneumatic compressionIPC or 60 for
LMWH
Gender: Male 47 Female 73
Mean age: 37.1 (R 18-76)
Inclusion Criteria: polytrauma with severe head/spinal injuries
Exclusion Criteria: younger than 14 years old were. excluded, as were individuals with
hepatic or urinary dysfunction, a spinal cord injury, a history of DVT, or a high bleeding
risk (platelets < 100,000/µl or INR > 1.5) and those using anticoagulants. Patients with
continuing haemorrhage on control scans within 24 hours of admission or who required
craniotomy were excluded from the study
Type of Injury Not reported (Blunt?).
Location of trauma: Spine: 5 to 6Head: 55 to 54 Face: Not reported Chest: Not reported
Abdomen: Not reported Pelvis: Not reported Extremity: Not reported PolItrauma (more
than one): Not reported
Severity of trauma (ISS, RTS) or not reported: ISS mean: ISS mean Intervention A 18.
3 +/- 3.2 (4-35) Intervetion B 19.5 +/- 1.7 ( 4-45)
Type of management (Operatory , Non operatory, both or not reported): Not reported
Interventions IPC Intermitent pneumatic Compression the IPC patients were placed on below-knee
IPC devices (Prophylactic D.V.T System, modelAC
550; Flowtron Excell, Bedfordshire, UK) or another IPC device (AV Impulse System,
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Kurtoglu 2004 (Continued)
Duo; Novamedix, Andover, UK) for prophylaxis
LMWH group patients received enoxaparin sodium 40 mg/
day (Clexane; Aventis, Strasbourg, France
Outcomes Diagnosticmethod forDVT:Venous duplex colour-flowDoppler ultrasonography of the
lower extremities was obtained on admission to the ICU, each week of hospitalisation,
and 1 week after discharge for all patients
Diagnostic method for PE: Patients with a suspected DVT, those whose clinical status
was deteriorating, and
those who displayed a sudden change in blood gas levels were subjected to spiral CT
scanning. Pulmonary CT examinations were undertakenwith a Somatom Plus-S scanner
(Siemens, Erlangen, Germany
Any bleeding ? Yes
Major Bleeding macroscopic hematuria without renal injury, overt bleeding, and a sud-
den drop in the haemoglobin level ( 2 g/dl)
Minor BleedingMicroscopic hematuria, hematoma at the site of injection, and a drop in
the haemoglobin level of less than 2 g/dl were considered minor bleeding complications
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No (Alternate selection)
Allocation concealment (selection bias) High risk The patients were randomly allocated by alternate
selection to either group
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Unclear (Not described)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients randomised were analysed
Selective reporting (reporting bias) Unclear risk Protocol not known.
Stannard 2001
Methods Randomized clinical trial
Participants 107 participants randomised: 54 for thigh-calf low-pressure sequential-compression de-
vice 53 for calf-foot high-pressure pulsatile-compression pump
Gender: Not reported
Mean age: Not reported
Inclusion Criteria: blunt trauma causing a pelvic or acetabular
fracture with a pattern requiring surgical fixation, an age of at
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least sixteen years, and an ability and willingness to comply
with both the mechanical prophylaxis protocol and the
screening studies for deep-vein thrombosis
Exclusion Criteria: a history of venous thromboembolic disease, initiation
of mechanical compression more than seventy-two hours
following the injury, a body habitus or weight that made it difficult
for the patient to fit in the magnetic resonance imaging
scanner, or a stable injury that did not require surgical treatment
Type of Injury: all were blunt
Location of trauma: Spine: Not reported Head: Not reported Face: Not reported Chest:
Not reported Abdomen: Not reported Pelvis:All were pelvis (they don´ t say how many
per group Extremity: Not reported Polytrauma Not reported
Severity of trauma (ISS, RTS) or not reported: ISS mean: thigh-calf low-pressure se-
quential-compression : 19.8 (9-59) calf-foot high-pressure pulsatile-compression pump:
16.1(9-50)
Type of management Operatory
Interventions - a thigh-calf low pressure sequential- compression device (Kendall SCD; Kendall,Mans-
field, Massachusetts)
- combination sequential pump that covers the calf and foot (PlexiPulse;NuTech, Kinetic
Concepts,
San Antonio, Texas).
Outcomes Diagnostic method for DVT: Doppler ultrasonography and MRI venogram
Diagnostic method for PE: not reported.
Any bleeding ? No.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation table.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk All studieswere interpreted by radiologists blinded regarding
the type of prophylaxis against deep-vein thrombosis and
the result of the other study
Incomplete outcome data (attrition bias)
All outcomes
High risk “Thirty-three patients who were initially enrolled in the
study did not complete it. The reasons for withdrawal from
the study included claustrophobia (six patients); death (six)
(no patient died because of a thromboembolic event); refusal
to undergo magnetic resonance venography (five); inadver-
tent initiation of anticoagulation by another service (five);
discharge before the appropriate studies had been performed
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(three); inability of the patient to fit in the magnetic reso-
nance scanner (two); inability of the patient to remain im-
mobile during the magnetic resonance imaging secondary
to a closed head injury (two); prior venous thromboembolic
disease missed on the initial screening (two); inadvertent
switching of
the pump types (one); and pregnancy (one). The pa-
tients who withdrew had a total of three deep-vein throm-
boses, which were not included in the statistical analysis”.
(Stannard 2001, page 1048)
Selective reporting (reporting bias) Unclear risk Protocol not known.
Stannard 2006
Methods Randomized clinical trial
Participants 200 participants randomised (Group A 97 LMWH and Group B 103 for PlexiPulse foot
pump and LMWH
Gender: Not reported
Mean age: Group A 38.2 (19-75) Group B 41.0 (19-80)
Inclusion Criteria: The inclusion criteria were blunt trauma and at least one of the
following findings: an Abbreviated Injury Score of 3 or more and a long-bone fracture,
multiple (two or more) long-bone fractures,
or an age of more than fifty-five years and a long-bone fracture. In addition, all patients
were more than eighteen years of age, had no contraindications to anticoagulation, and
had been admitted to our hospital less than seventy-two hours after the time of trauma
or had a negative magnetic resonance venogram
prior to enrolment.
Exclusion Criteria: Exclusion criteria included renal insufficiency; severe cranial or spinal
cord injury; the use of anticoagulants; any contraindication to anticoagulation, including
severe active bleeding; pregnancy; a history of venous thromboembolic disease; any
contraindication to magnetic resonance venography; the presence of a vena cava filter;
and severe ocular trauma. Cranial and ocular trauma associated with
bleeding and a risk of increased intracranial or ocular pressure was considered severe and
led to exclusion from the study
Type of Injury Blunt trauma
Location of trauma: Spine: A 2 to B 6Head:No Face: NoChest:No Abdomen:No Pelvis:
A 89 to B 85 Extremity: A 161 To B 141 PolItrauma (more than one): No
Severity of trauma ISS mean:Group A 14.41 (8-57) Group B 14.43 (4-41)
Type of management : Not reported
Interventions Group A LMWH 30 mg sc BID until the discharge
Group B LMWH 30 mg sc BID until the discharge and PlexiPulse foot pumps (Kinetic
Concepts, San Antonio, Texas)
Outcomes DVTDupplex ultrasound and venousMRI before the discharge or before it was indicated
MRI
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation program.
Allocation concealment (selection bias) Unclear risk Not described in the full text article.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Two radiologists (including one of the authors , who were
blinded with regard to the type of deep-vein thrombosis
treatment, reviewed the coronal reformatted multiple- in-
tensity projections and source axial images. When there was
a discrepancy between the radiologists with regard to the
correct interpretation, the radiologists reviewed the studies
in question together and came to a consensus
Incomplete outcome data (attrition bias)
All outcomes
High risk Two hundred and twenty-four patients were enrolled, and
200 completed the entire protocol.
Selective reporting (reporting bias) Unclear risk Protocol not known.
Velmahos 2005
Methods Randomized clinical trial
Participants 47 participants randomised (26 for Muscle electrostimulation (MEST) and 21 for Con-
trol)
Gender: MEST: male 21/female 5 to Control: male 16/female 5
Mean age: 32 ± 15 years for MEST to 45 ± 21 years for Control
Inclusion Criteria: trauma (Injury Severity Score higher than 9) and had contraindica-
tions for receiving prophylactic heparin (unfractionated or low molecular weight) were
considered for inclusion in the study. Such
patients were those with (a) significant head injuries, (b) operations for extensive organ
injuries,
(c) major retroperitoneal hematomas, (d) liver, spleen, or kidney injuries higher than
Grade II,
managed nonoperatively, or (e) other injuries that at the discretion of the trauma surgeon
were
deemed to be associated with a high likelihood for bleeding. Additional inclusion criteria
were (1)
anticipated survival for longer than 7 days, (2) anticipated hospital stay of longer than 7
days, and
(3) randomisation within 24 hours of injury.
Exclusion Criteria: a) age less than 18 years, (b) known allergy to contrast material,
precluding
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the use of venography, (c) cardiac demand pacemakers or other implanted stimulators
or implants
containingmetal partswithin the area of treatment, (d) spastic paralysis, (e) local infection
at the
site of application, and (f ) history or present evidence of venous thrombosis
Type of Injury (blunt , penetrated, both or not reported): Blunt: 34 Penetrating: 13.
MEST: Blunt: 18 Penetrating: 8. Control: Blunt: 16 Penetrating: 5
Location of trauma: Spine: 5 to1 Head: 7 to 1 Face: Not reported Chest: Not reported
Abdomen: Not reported Pelvis: Not reported Extremity: 9 to 13 PolItrauma (more than
one): Not reported
Severity of trauma (ISS, RTS) or not reported: ISS mean: MEST: 20 Control: 18
Type of management (Operatory , Non operatory, both or not reported): MEST: oper-
atory: 19 Control: operatory: 21
Interventions Muscle electrostimulation (MEST): MEST patients received two 30-minute sessions
daily, one in the morning
and one in the evening, by using the Lymphavision stimulator (Bexley Trading, San
Rafael, Calif ).
Electrodes were placed at the calves and medial thighs of both extremities. Voltage was
applied
gradually (0-120 V) to obtain a slight visible twitch of the muscles, usually evident by
movement of the
toes. Stimuli were 3 milliseconds long at a frequency of 1.75 Hz (105/minute) with
inversion of




Outcomes Diagnostic method for DVT: Venography or duplex
Diagnostic method for PE: Not described
Any bleeding ? None
Notes Co-interventions:Patients of both groups were allowed to have standard prophylaxis by
subcutaneous unfractionated or low-molecular-weight heparin when the contraindica-
tion for its use was no longer
present (usually 3-5 days after admission) and/or by SCD if the extremities were not
injured at the site of placement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized by a computer generated system
Allocation concealment (selection bias) Unclear risk Not described.
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Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients were analysed.
Selective reporting (reporting bias) Unclear risk Protocol not known.
Yanar 2007
Methods Randomized clinical trial (Abstract)
Participants 120 patients three groups. They don´ t say inclusion or exclusion criteria
Interventions Group A IPC
Group B IPC +LMWH
Group C LMWH
Outcomes Diagnostic method for DVT: duplex ultrasound
Diagnostic method for PE: CT Scan
Any bleeding ? Not reported
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Incomplete data in the abstract.
Allocation concealment (selection bias) Unclear risk Incomplete data in the abstract.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Incomplete data in the abstract.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Incomplete data in the abstract.
Selective reporting (reporting bias) Unclear risk Protocol not known.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Breyer 1986 Insufficient information given in the abstract to consider for inclusion
Greenfiel 1997 It is not randomised.
Haas 2003 It is an abstract and included patients with hip fractures and outpatients
Holzheimer 2004 It is a review.
Murakami 2003 DVT is not an outcome
Reilmann 1986 It is not a RCT.
Wolf 1992 It was not for trauma patients.
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D A T A A N D A N A L Y S E S
Comparison 1. Prophylaxis vs No prophylaxis




participants Statistical method Effect size
1 Deep Venous Thrombosis
(DVT)
4 997 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.32, 0.84]
2 Pulmonary Embolism (PE) 4 997 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.29, 1.43]
3 Mortality 4 997 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.20, 1.70]
4 Bleeding 3 553 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Mechanical prophylaxis vs No prophylaxis




participants Statistical method Effect size
1 DVT 5 907 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.34, 0.90]
2 PE 5 907 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.36, 1.66]
3 Mortality 5 907 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.27, 2.04]
4 Bleeding 4 603 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Pharmacological prophylaxis vs Mechanical prophylaxis




participants Statistical method Effect size
1 DVT 6 1033 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.25, 0.95]
2 PE 6 1033 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.36, 2.42]
3 Mortality 6 1033 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.44, 5.16]
4 Bleeding 5 953 Risk Ratio (M-H, Fixed, 95% CI) 2.04 [1.08, 3.86]
5 Major bleeding 3 764 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.26, 4.06]
6 Minor bleeding 3 764 Risk Ratio (M-H, Fixed, 95% CI) 2.37 [1.13, 4.98]
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participants Statistical method Effect size
1 DVT 2 331 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.50, 0.94]
2 PE 2 331 Risk Ratio (M-H, Fixed, 95% CI) 3.16 [0.13, 76.91]
3 Mortality 2 331 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Bleeding 2 331 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.63, 4.22]
5 Major bleeding 2 331 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.55, 3.85]
6 Minor bleeding 2 331 Risk Ratio (M-H, Fixed, 95% CI) 3.16 [0.13, 76.91]
Comparison 5. Mechanical + pharmacological prophylaxis vs Pharmacological




participants Statistical method Effect size
1 DVT 3 507 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.19, 0.60]
2 PE 3 507 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.05, 2.01]
3 Mortality 3 507 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.30]
4 Bleeding 1 200 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.56, 1.78]
Comparison 6. Mechanical + pharmacological prophylaxis vs Mechanical prophylaxis




participants Statistical method Effect size
1 DVT 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.10, 2.58]
2 PE 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.30]
3 Mortality 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 5.30]
Comparison 7. Thigh-calf vs Calf-foot




participants Statistical method Effect size
1 DVT 3 373 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.37, 1.32]
2 PE 3 373 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.12, 5.10]
3 Mortality 3 373 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Bleeding 3 373 Risk Ratio (M-H, Fixed, 95% CI) 3.04 [0.13, 73.44]
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Comparison 8. Prophylaxis vs No prophylaxis (sensitivity analysis)




participants Statistical method Effect size
1 DVT 1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.12, 1.11]
2 PE 1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.27, 2.00]
Comparison 9. Mechanical prophylaxis vs No prophylaxis (sensitivity analysis)




participants Statistical method Effect size
1 DVT 1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.12, 1.11]
2 PE 1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.27, 2.00]
Comparison 10. LMWH vs UH (Sensitivity analysis)




participants Statistical method Effect size
1 DVT 1 265 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.51, 0.97]
2 PE 1 265 Risk Ratio (M-H, Fixed, 95% CI) 3.16 [0.13, 76.91]
3 Mortality 1 265 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Bleeding 1 265 Risk Ratio (M-H, Fixed, 95% CI) 5.27 [0.62, 44.51]
5 Major Bleeding 1 265 Risk Ratio (M-H, Fixed, 95% CI) 4.22 [0.48, 37.23]
6 Minor Bleeding 1 265 Risk Ratio (M-H, Fixed, 95% CI) 3.16 [0.13, 76.91]
Comparison 11. Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis)




participants Statistical method Effect size
1 DVT 1 442 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.41]
2 PE 1 442 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.06, 16.32]
3 Mortality 1 442 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Bleeding 1 442 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.71, 3.95]
5 Major bleeding 1 442 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.26, 4.06]
6 Minor bleeding 1 442 Risk Ratio (M-H, Fixed, 95% CI) 2.31 [0.72, 7.40]
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Analysis 1.1. Comparison 1 Prophylaxis vs No prophylaxis, Outcome 1 Deep Venous Thrombosis (DVT).
Review: Thromboprophylaxis for trauma patients
Comparison: 1 Prophylaxis vs No prophylaxis
Outcome: 1 Deep Venous Thrombosis (DVT)
Study or subgroup Prophylaxis No Prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dennis 1993 8/281 10/114 34.7 % 0.32 [ 0.13, 0.80 ]
Fisher 1995 4/145 12/159 27.9 % 0.37 [ 0.12, 1.11 ]
Knudson 1994 All groups 6/121 9/130 21.2 % 0.72 [ 0.26, 1.95 ]
Velmahos 2005 7/26 6/21 16.2 % 0.94 [ 0.37, 2.38 ]
Total (95% CI) 573 424 100.0 % 0.52 [ 0.32, 0.84 ]
Total events: 25 (Prophylaxis), 37 (No Prophylaxis)
Heterogeneity: Chi2 = 3.41, df = 3 (P = 0.33); I2 =12%
Test for overall effect: Z = 2.67 (P = 0.0076)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prophylaxis Favours no prophylaxis
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Analysis 1.2. Comparison 1 Prophylaxis vs No prophylaxis, Outcome 2 Pulmonary Embolism (PE).
Review: Thromboprophylaxis for trauma patients
Comparison: 1 Prophylaxis vs No prophylaxis
Outcome: 2 Pulmonary Embolism (PE)
Study or subgroup Prophylaxis No Prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dennis 1993 2/281 2/114 19.7 % 0.41 [ 0.06, 2.85 ]
Fisher 1995 6/145 9/159 59.4 % 0.73 [ 0.27, 2.00 ]
Knudson 1994 All groups 1/121 2/130 13.3 % 0.54 [ 0.05, 5.85 ]
Velmahos 2005 1/26 1/21 7.6 % 0.81 [ 0.05, 12.16 ]
Total (95% CI) 573 424 100.0 % 0.65 [ 0.29, 1.43 ]
Total events: 10 (Prophylaxis), 14 (No Prophylaxis)
Heterogeneity: Chi2 = 0.33, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prophylaxis Favours no prophylaxis
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Analysis 1.3. Comparison 1 Prophylaxis vs No prophylaxis, Outcome 3 Mortality.
Review: Thromboprophylaxis for trauma patients
Comparison: 1 Prophylaxis vs No prophylaxis
Outcome: 3 Mortality
Study or subgroup Prophylaxis No Prophylaxis Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dennis 1993 3/281 4/114 0.30 [ 0.07, 1.34 ]
Fisher 1995 0/145 0/159 0.0 [ 0.0, 0.0 ]
Knudson 1994 All groups 1/121 1/130 1.07 [ 0.07, 16.99 ]
Velmahos 2005 2/26 1/21 1.62 [ 0.16, 16.61 ]
Total (95% CI) 573 424 0.59 [ 0.20, 1.70 ]
Total events: 6 (Prophylaxis), 6 (No Prophylaxis)
Heterogeneity: Chi2 = 1.67, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prophylaxis Favours no prophylaxis
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Analysis 1.4. Comparison 1 Prophylaxis vs No prophylaxis, Outcome 4 Bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 1 Prophylaxis vs No prophylaxis
Outcome: 4 Bleeding
Study or subgroup Prophylaxis No Prophylaxis Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dennis 1993 0/281 0/114 0.0 [ 0.0, 0.0 ]
Knudson 1994 All groups 0/45 0/66 0.0 [ 0.0, 0.0 ]
Velmahos 2005 0/26 0/21 0.0 [ 0.0, 0.0 ]
Total (95% CI) 352 201 0.0 [ 0.0, 0.0 ]
Total events: 0 (Prophylaxis), 0 (No Prophylaxis)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prophylaxis Favours no prophylaxis
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Analysis 2.1. Comparison 2 Mechanical prophylaxis vs No prophylaxis, Outcome 1 DVT.
Review: Thromboprophylaxis for trauma patients
Comparison: 2 Mechanical prophylaxis vs No prophylaxis
Outcome: 1 DVT
Study or subgroup Mechanical No prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Knudson 1994 group I 4/32 2/64 3.5 % 4.00 [ 0.77, 20.69 ]
Knudson 1994 group III 0/26 5/39 11.6 % 0.13 [ 0.01, 2.34 ]
Velmahos 2005 7/26 6/21 17.4 % 0.94 [ 0.37, 2.38 ]
Fisher 1995 4/145 12/159 30.1 % 0.37 [ 0.12, 1.11 ]
Dennis 1993 8/281 10/114 37.4 % 0.32 [ 0.13, 0.80 ]
Total (95% CI) 510 397 100.0 % 0.55 [ 0.34, 0.90 ]
Total events: 23 (Mechanical), 35 (No prophylaxis)
Heterogeneity: Chi2 = 9.66, df = 4 (P = 0.05); I2 =59%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Mechanical prophylaxis vs No prophylaxis, Outcome 2 PE.
Review: Thromboprophylaxis for trauma patients
Comparison: 2 Mechanical prophylaxis vs No prophylaxis
Outcome: 2 PE
Study or subgroup Mechanical No prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dennis 1993 2/281 2/114 20.4 % 0.41 [ 0.06, 2.85 ]
Fisher 1995 6/145 9/159 61.5 % 0.73 [ 0.27, 2.00 ]
Knudson 1994 group I 0/32 1/64 7.2 % 0.66 [ 0.03, 15.68 ]
Knudson 1994 group III 1/26 0/39 2.9 % 4.44 [ 0.19, 105.09 ]
Velmahos 2005 1/26 1/21 7.9 % 0.81 [ 0.05, 12.16 ]
Total (95% CI) 510 397 100.0 % 0.77 [ 0.36, 1.66 ]
Total events: 10 (Mechanical), 13 (No prophylaxis)
Heterogeneity: Chi2 = 1.62, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Mechanical prophylaxis vs No prophylaxis, Outcome 3 Mortality.
Review: Thromboprophylaxis for trauma patients
Comparison: 2 Mechanical prophylaxis vs No prophylaxis
Outcome: 3 Mortality
Study or subgroup Mechanical No prophylaxis Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dennis 1993 3/281 4/114 0.30 [ 0.07, 1.34 ]
Fisher 1995 0/145 0/159 0.0 [ 0.0, 0.0 ]
Knudson 1994 group I 0/32 0/64 0.0 [ 0.0, 0.0 ]
Knudson 1994 group III 1/26 0/39 4.44 [ 0.19, 105.09 ]
Velmahos 2005 2/26 1/21 1.62 [ 0.16, 16.61 ]
Total (95% CI) 510 397 0.74 [ 0.27, 2.04 ]
Total events: 6 (Mechanical), 5 (No prophylaxis)
Heterogeneity: Chi2 = 3.05, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Mechanical prophylaxis vs No prophylaxis, Outcome 4 Bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 2 Mechanical prophylaxis vs No prophylaxis
Outcome: 4 Bleeding
Study or subgroup Mechanical No prophylaxis Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Velmahos 2005 0/26 0/21 0.0 [ 0.0, 0.0 ]
Knudson 1994 group I 0/32 0/64 0.0 [ 0.0, 0.0 ]
Dennis 1993 0/281 0/114 0.0 [ 0.0, 0.0 ]
Knudson 1994 group III 0/26 0/39 0.0 [ 0.0, 0.0 ]
Total (95% CI) 365 238 0.0 [ 0.0, 0.0 ]
Total events: 0 (Mechanical), 0 (No prophylaxis)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 1 DVT.
Review: Thromboprophylaxis for trauma patients
Comparison: 3 Pharmacological prophylaxis vs Mechanical prophylaxis
Outcome: 1 DVT
Study or subgroup Pharmacologycal Mechanical Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 1/218 6/224 24.5 % 0.17 [ 0.02, 1.41 ]
Knudson 1992 3/37 5/76 13.5 % 1.23 [ 0.31, 4.88 ]
Knudson 1994 group I 1/44 4/32 19.1 % 0.18 [ 0.02, 1.55 ]
Knudson 1996 1/120 2/82 9.8 % 0.34 [ 0.03, 3.71 ]
Kurtoglu 2004 3/60 4/60 16.5 % 0.75 [ 0.18, 3.21 ]
Yanar 2007 2/40 4/40 16.5 % 0.50 [ 0.10, 2.58 ]
Total (95% CI) 519 514 100.0 % 0.48 [ 0.25, 0.95 ]
Total events: 11 (Pharmacologycal), 25 (Mechanical)
Heterogeneity: Chi2 = 3.94, df = 5 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 2 PE.
Review: Thromboprophylaxis for trauma patients
Comparison: 3 Pharmacological prophylaxis vs Mechanical prophylaxis
Outcome: 2 PE
Study or subgroup Pharmacologycal Mechanical Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 1/218 1/224 1.03 [ 0.06, 16.32 ]
Knudson 1992 1/37 6/76 0.34 [ 0.04, 2.74 ]
Knudson 1994 group I 0/44 0/32 0.0 [ 0.0, 0.0 ]
Knudson 1996 0/120 0/82 0.0 [ 0.0, 0.0 ]
Kurtoglu 2004 4/60 2/60 2.00 [ 0.38, 10.51 ]
Yanar 2007 2/40 2/40 1.00 [ 0.15, 6.76 ]
Total (95% CI) 519 514 0.94 [ 0.36, 2.42 ]
Total events: 8 (Pharmacologycal), 11 (Mechanical)
Heterogeneity: Chi2 = 1.71, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 3 Mortality.
Review: Thromboprophylaxis for trauma patients
Comparison: 3 Pharmacological prophylaxis vs Mechanical prophylaxis
Outcome: 3 Mortality
Study or subgroup Pharmacologycal Mechanical Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 0/218 0/224 0.0 [ 0.0, 0.0 ]
Knudson 1992 0/37 0/76 0.0 [ 0.0, 0.0 ]
Knudson 1994 group I 0/44 0/32 0.0 [ 0.0, 0.0 ]
Knudson 1996 0/120 0/82 0.0 [ 0.0, 0.0 ]
Kurtoglu 2004 4/60 2/60 2.00 [ 0.38, 10.51 ]
Yanar 2007 2/40 2/40 1.00 [ 0.15, 6.76 ]
Total (95% CI) 519 514 1.50 [ 0.44, 5.16 ]
Total events: 6 (Pharmacologycal), 4 (Mechanical)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 4 Bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 3 Pharmacological prophylaxis vs Mechanical prophylaxis
Outcome: 4 Bleeding
Study or subgroup Pharmacologycal Mechanical Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 13/218 8/224 1.67 [ 0.71, 3.95 ]
Knudson 1992 0/37 0/76 0.0 [ 0.0, 0.0 ]
Knudson 1994 group I 0/44 0/32 0.0 [ 0.0, 0.0 ]
Knudson 1996 6/120 0/82 8.92 [ 0.51, 156.15 ]
Kurtoglu 2004 9/60 5/60 1.80 [ 0.64, 5.06 ]
Total (95% CI) 479 474 2.04 [ 1.08, 3.86 ]
Total events: 28 (Pharmacologycal), 13 (Mechanical)
Heterogeneity: Chi2 = 1.28, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.029)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 5 Major
bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 3 Pharmacological prophylaxis vs Mechanical prophylaxis
Outcome: 5 Major bleeding
Study or subgroup Pharmacologycal Mechanical Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 4/218 4/224 1.03 [ 0.26, 4.06 ]
Knudson 1996 0/120 0/82 0.0 [ 0.0, 0.0 ]
Kurtoglu 2004 0/60 0/60 0.0 [ 0.0, 0.0 ]
Total (95% CI) 398 366 1.03 [ 0.26, 4.06 ]
Total events: 4 (Pharmacologycal), 4 (Mechanical)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Pharmacological prophylaxis vs Mechanical prophylaxis, Outcome 6 Minor
bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 3 Pharmacological prophylaxis vs Mechanical prophylaxis
Outcome: 6 Minor bleeding
Study or subgroup Pharmacologycal Mechanical Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 9/218 4/224 41.4 % 2.31 [ 0.72, 7.40 ]
Knudson 1996 5/120 0/82 6.2 % 7.55 [ 0.42, 134.63 ]
Kurtoglu 2004 9/60 5/60 52.4 % 1.80 [ 0.64, 5.06 ]
Total (95% CI) 398 366 100.0 % 2.37 [ 1.13, 4.98 ]
Total events: 23 (Pharmacologycal), 9 (Mechanical)
Heterogeneity: Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 LWMH vs UH, Outcome 1 DVT.
Review: Thromboprophylaxis for trauma patients
Comparison: 4 LWMH vs UH
Outcome: 1 DVT
Study or subgroup LMWH UH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohn 1999 0/34 2/32 4.2 % 0.19 [ 0.01, 3.78 ]
Geerts 1996 40/129 60/136 95.8 % 0.70 [ 0.51, 0.97 ]
Total (95% CI) 163 168 100.0 % 0.68 [ 0.50, 0.94 ]
Total events: 40 (LMWH), 62 (UH)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 LWMH vs UH, Outcome 2 PE.
Review: Thromboprophylaxis for trauma patients
Comparison: 4 LWMH vs UH
Outcome: 2 PE
Study or subgroup LMWH UH Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohn 1999 0/34 0/32 0.0 [ 0.0, 0.0 ]
Geerts 1996 1/129 0/136 3.16 [ 0.13, 76.91 ]
Total (95% CI) 163 168 3.16 [ 0.13, 76.91 ]
Total events: 1 (LMWH), 0 (UH)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 LWMH vs UH, Outcome 3 Mortality.
Review: Thromboprophylaxis for trauma patients
Comparison: 4 LWMH vs UH
Outcome: 3 Mortality
Study or subgroup LMWH UH Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohn 1999 0/34 0/32 0.0 [ 0.0, 0.0 ]
Geerts 1996 0/129 0/136 0.0 [ 0.0, 0.0 ]
Total (95% CI) 163 168 0.0 [ 0.0, 0.0 ]
Total events: 0 (LMWH), 0 (UH)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 LWMH vs UH, Outcome 4 Bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 4 LWMH vs UH
Outcome: 4 Bleeding
Study or subgroup LMWH UH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohn 1999 5/34 5/32 84.1 % 0.94 [ 0.30, 2.95 ]
Geerts 1996 5/129 1/136 15.9 % 5.27 [ 0.62, 44.51 ]
Total (95% CI) 163 168 100.0 % 1.63 [ 0.63, 4.22 ]
Total events: 10 (LMWH), 6 (UH)
Heterogeneity: Chi2 = 2.05, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 LWMH vs UH, Outcome 5 Major bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 4 LWMH vs UH
Outcome: 5 Major bleeding
Study or subgroup LMWH UH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohn 1999 5/34 5/32 84.1 % 0.94 [ 0.30, 2.95 ]
Geerts 1996 4/129 1/136 15.9 % 4.22 [ 0.48, 37.23 ]
Total (95% CI) 163 168 100.0 % 1.46 [ 0.55, 3.85 ]
Total events: 9 (LMWH), 6 (UH)
Heterogeneity: Chi2 = 1.48, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 LWMH vs UH, Outcome 6 Minor bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 4 LWMH vs UH
Outcome: 6 Minor bleeding
Study or subgroup LMWH UH Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cohn 1999 0/34 0/32 0.0 [ 0.0, 0.0 ]
Geerts 1996 1/129 0/136 3.16 [ 0.13, 76.91 ]
Total (95% CI) 163 168 3.16 [ 0.13, 76.91 ]
Total events: 1 (LMWH), 0 (UH)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Mechanical + pharmacological prophylaxis vs Pharmacological, Outcome 1 DVT.
Review: Thromboprophylaxis for trauma patients





prophylaxis Pharmacologycal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fuchs 2005 4/111 29/116 64.8 % 0.14 [ 0.05, 0.40 ]
Stannard 2006 9/103 13/97 30.6 % 0.65 [ 0.29, 1.46 ]
Yanar 2007 2/40 2/40 4.6 % 1.00 [ 0.15, 6.76 ]
Total (95% CI) 254 253 100.0 % 0.34 [ 0.19, 0.60 ]
Total events: 15 (Mechanical plus pharmacologycal prophylaxis), 44 (Pharmacologycal)
Heterogeneity: Chi2 = 6.52, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 3.74 (P = 0.00019)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Mechanical + pharmacological prophylaxis vs Pharmacological, Outcome 2 PE.
Review: Thromboprophylaxis for trauma patients





prophylaxis Pharmacologycal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fuchs 2005 0/111 0/116 0.0 [ 0.0, 0.0 ]
Stannard 2006 0/103 2/97 0.19 [ 0.01, 3.88 ]
Yanar 2007 1/40 2/40 0.50 [ 0.05, 5.30 ]
Total (95% CI) 254 253 0.32 [ 0.05, 2.01 ]
Total events: 1 (Mechanical plus pharmacologycal prophylaxis), 4 (Pharmacologycal)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Mechanical + pharmacological prophylaxis vs Pharmacological, Outcome 3
Mortality.
Review: Thromboprophylaxis for trauma patients





prophylaxis Pharmacologycal Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fuchs 2005 0/111 0/116 0.0 [ 0.0, 0.0 ]
Stannard 2006 0/103 0/97 0.0 [ 0.0, 0.0 ]
Yanar 2007 1/40 2/40 0.50 [ 0.05, 5.30 ]
Total (95% CI) 254 253 0.50 [ 0.05, 5.30 ]
Total events: 1 (Mechanical plus pharmacologycal prophylaxis), 2 (Pharmacologycal)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Mechanical + pharmacological prophylaxis vs Pharmacological, Outcome 4
Bleeding.
Review: Thromboprophylaxis for trauma patients





prophylaxis Pharmacologycal Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stannard 2006 19/103 18/97 100.0 % 0.99 [ 0.56, 1.78 ]
Total (95% CI) 103 97 100.0 % 0.99 [ 0.56, 1.78 ]
Total events: 19 (Mechanical plus pharmacologycal prophylaxis), 18 (Pharmacologycal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Mechanical + pharmacological prophylaxis vs Mechanical prophylaxis, Outcome
1 DVT.
Review: Thromboprophylaxis for trauma patients







prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yanar 2007 2/40 4/40 100.0 % 0.50 [ 0.10, 2.58 ]
Total (95% CI) 40 40 100.0 % 0.50 [ 0.10, 2.58 ]
Total events: 2 (Mechanical plus farmacologycal prophylaxis), 4 (Mechanical prophylaxis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Mechanical + pharmacological prophylaxis vs Mechanical prophylaxis, Outcome
2 PE.
Review: Thromboprophylaxis for trauma patients







prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yanar 2007 1/40 2/40 100.0 % 0.50 [ 0.05, 5.30 ]
Total (95% CI) 40 40 100.0 % 0.50 [ 0.05, 5.30 ]
Total events: 1 (Mechanical plus farmacologycal prophylaxis), 2 (Mechanical prophylaxis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Mechanical + pharmacological prophylaxis vs Mechanical prophylaxis, Outcome
3 Mortality.
Review: Thromboprophylaxis for trauma patients







prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yanar 2007 1/40 2/40 100.0 % 0.50 [ 0.05, 5.30 ]
Total (95% CI) 40 40 100.0 % 0.50 [ 0.05, 5.30 ]
Total events: 1 (Mechanical plus farmacologycal prophylaxis), 2 (Mechanical prophylaxis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Thigh-calf vs Calf-foot, Outcome 1 DVT.
Review: Thromboprophylaxis for trauma patients
Comparison: 7 Thigh-calf vs Calf-foot
Outcome: 1 DVT
Study or subgroup Thigh- Calf Calf-Foot Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anglen 1998 0/49 3/68 14.1 % 0.20 [ 0.01, 3.73 ]
Elliot 1999 4/74 13/75 61.8 % 0.31 [ 0.11, 0.91 ]
Stannard 2001 10/54 5/53 24.1 % 1.96 [ 0.72, 5.36 ]
Total (95% CI) 177 196 100.0 % 0.69 [ 0.37, 1.32 ]
Total events: 14 (Thigh- Calf), 21 (Calf-Foot)
Heterogeneity: Chi2 = 6.95, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Thigh-calf vs Calf-foot, Outcome 2 PE.
Review: Thromboprophylaxis for trauma patients
Comparison: 7 Thigh-calf vs Calf-foot
Outcome: 2 PE
Study or subgroup Thigh- Calf Calf-Foot Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anglen 1998 0/49 2/68 0.28 [ 0.01, 5.62 ]
Elliot 1999 0/74 0/75 0.0 [ 0.0, 0.0 ]
Stannard 2001 1/54 0/53 2.95 [ 0.12, 70.72 ]
Total (95% CI) 177 196 0.79 [ 0.12, 5.10 ]
Total events: 1 (Thigh- Calf), 2 (Calf-Foot)
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =11%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Thigh-calf vs Calf-foot, Outcome 3 Mortality.
Review: Thromboprophylaxis for trauma patients
Comparison: 7 Thigh-calf vs Calf-foot
Outcome: 3 Mortality
Study or subgroup Thigh- Calf Calf-Foot Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anglen 1998 0/49 0/68 0.0 [ 0.0, 0.0 ]
Elliot 1999 0/74 0/75 0.0 [ 0.0, 0.0 ]
Stannard 2001 0/54 0/53 0.0 [ 0.0, 0.0 ]
Total (95% CI) 177 196 0.0 [ 0.0, 0.0 ]
Total events: 0 (Thigh- Calf), 0 (Calf-Foot)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours thigh - calf Favours calf - foot
Analysis 7.4. Comparison 7 Thigh-calf vs Calf-foot, Outcome 4 Bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 7 Thigh-calf vs Calf-foot
Outcome: 4 Bleeding
Study or subgroup Thigh- Calf Calf-Foot Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Anglen 1998 0/49 0/68 0.0 [ 0.0, 0.0 ]
Elliot 1999 1/74 0/75 3.04 [ 0.13, 73.44 ]
Stannard 2001 0/54 0/53 0.0 [ 0.0, 0.0 ]
Total (95% CI) 177 196 3.04 [ 0.13, 73.44 ]
Total events: 1 (Thigh- Calf), 0 (Calf-Foot)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Prophylaxis vs No prophylaxis (sensitivity analysis), Outcome 1 DVT.
Review: Thromboprophylaxis for trauma patients
Comparison: 8 Prophylaxis vs No prophylaxis (sensitivity analysis)
Outcome: 1 DVT
Study or subgroup Prophylaxis No prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fisher 1995 4/145 12/159 100.0 % 0.37 [ 0.12, 1.11 ]
Total (95% CI) 145 159 100.0 % 0.37 [ 0.12, 1.11 ]
Total events: 4 (Prophylaxis), 12 (No prophylaxis)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prophylaxis Favours no prophylaxis
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Analysis 8.2. Comparison 8 Prophylaxis vs No prophylaxis (sensitivity analysis), Outcome 2 PE.
Review: Thromboprophylaxis for trauma patients
Comparison: 8 Prophylaxis vs No prophylaxis (sensitivity analysis)
Outcome: 2 PE
Study or subgroup Prophylaxis No prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fisher 1995 6/145 9/159 100.0 % 0.73 [ 0.27, 2.00 ]
Total (95% CI) 145 159 100.0 % 0.73 [ 0.27, 2.00 ]
Total events: 6 (Prophylaxis), 9 (No prophylaxis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prophylaxis Favours no prophylaxis
Analysis 9.1. Comparison 9 Mechanical prophylaxis vs No prophylaxis (sensitivity analysis), Outcome 1 DVT.
Review: Thromboprophylaxis for trauma patients
Comparison: 9 Mechanical prophylaxis vs No prophylaxis (sensitivity analysis)
Outcome: 1 DVT
Study or subgroup Mechanical No prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fisher 1995 4/145 12/159 100.0 % 0.37 [ 0.12, 1.11 ]
Total (95% CI) 145 159 100.0 % 0.37 [ 0.12, 1.11 ]
Total events: 4 (Mechanical), 12 (No prophylaxis)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mechanical proph Favours no prophylaxis
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Analysis 9.2. Comparison 9 Mechanical prophylaxis vs No prophylaxis (sensitivity analysis), Outcome 2 PE.
Review: Thromboprophylaxis for trauma patients
Comparison: 9 Mechanical prophylaxis vs No prophylaxis (sensitivity analysis)
Outcome: 2 PE
Study or subgroup Mechanical No prophylaxis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fisher 1995 6/145 9/159 100.0 % 0.73 [ 0.27, 2.00 ]
Total (95% CI) 145 159 100.0 % 0.73 [ 0.27, 2.00 ]
Total events: 6 (Mechanical), 9 (No prophylaxis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mechanical proph Favours no prophylaxis
Analysis 10.1. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 1 DVT.
Review: Thromboprophylaxis for trauma patients
Comparison: 10 LMWH vs UH (Sensitivity analysis)
Outcome: 1 DVT
Study or subgroup LMWH UH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Geerts 1996 40/129 60/136 100.0 % 0.70 [ 0.51, 0.97 ]
Total (95% CI) 129 136 100.0 % 0.70 [ 0.51, 0.97 ]
Total events: 40 (LMWH), 60 (UH)
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.030)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UH
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Analysis 10.2. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 2 PE.
Review: Thromboprophylaxis for trauma patients
Comparison: 10 LMWH vs UH (Sensitivity analysis)
Outcome: 2 PE
Study or subgroup LMWH UH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Geerts 1996 1/129 0/136 100.0 % 3.16 [ 0.13, 76.91 ]
Total (95% CI) 129 136 100.0 % 3.16 [ 0.13, 76.91 ]
Total events: 1 (LMWH), 0 (UH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UH
Analysis 10.3. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 3 Mortality.
Review: Thromboprophylaxis for trauma patients
Comparison: 10 LMWH vs UH (Sensitivity analysis)
Outcome: 3 Mortality
Study or subgroup LMWH UH Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Geerts 1996 0/129 0/136 0.0 [ 0.0, 0.0 ]
Total (95% CI) 129 136 0.0 [ 0.0, 0.0 ]
Total events: 0 (LMWH), 0 (UH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UH
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Analysis 10.4. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 4 Bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 10 LMWH vs UH (Sensitivity analysis)
Outcome: 4 Bleeding
Study or subgroup LMWH UH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Geerts 1996 5/129 1/136 100.0 % 5.27 [ 0.62, 44.51 ]
Total (95% CI) 129 136 100.0 % 5.27 [ 0.62, 44.51 ]
Total events: 5 (LMWH), 1 (UH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UH
Analysis 10.5. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 5 Major Bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 10 LMWH vs UH (Sensitivity analysis)
Outcome: 5 Major Bleeding
Study or subgroup LMWH UH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Geerts 1996 4/129 1/136 100.0 % 4.22 [ 0.48, 37.23 ]
Total (95% CI) 129 136 100.0 % 4.22 [ 0.48, 37.23 ]
Total events: 4 (LMWH), 1 (UH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UH
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Analysis 10.6. Comparison 10 LMWH vs UH (Sensitivity analysis), Outcome 6 Minor Bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 10 LMWH vs UH (Sensitivity analysis)
Outcome: 6 Minor Bleeding
Study or subgroup LMWH UH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Geerts 1996 1/129 0/136 100.0 % 3.16 [ 0.13, 76.91 ]
Total (95% CI) 129 136 100.0 % 3.16 [ 0.13, 76.91 ]
Total events: 1 (LMWH), 0 (UH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours UH
Analysis 11.1. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis),
Outcome 1 DVT.
Review: Thromboprophylaxis for trauma patients
Comparison: 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis)
Outcome: 1 DVT
Study or subgroup Pharmacological Mechanical Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 1/218 6/224 100.0 % 0.17 [ 0.02, 1.41 ]
Total (95% CI) 218 224 100.0 % 0.17 [ 0.02, 1.41 ]
Total events: 1 (Pharmacological), 6 (Mechanical)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pharmacologycal Favours mechanical
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Analysis 11.2. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis),
Outcome 2 PE.
Review: Thromboprophylaxis for trauma patients
Comparison: 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis)
Outcome: 2 PE
Study or subgroup Pharmacological Mechanical Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 1/218 1/224 100.0 % 1.03 [ 0.06, 16.32 ]
Total (95% CI) 218 224 100.0 % 1.03 [ 0.06, 16.32 ]
Total events: 1 (Pharmacological), 1 (Mechanical)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pharmacologycal Favours mechanical
Analysis 11.3. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis),
Outcome 3 Mortality.
Review: Thromboprophylaxis for trauma patients
Comparison: 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis)
Outcome: 3 Mortality
Study or subgroup Pharmacological Mechanical Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 0/218 0/224 0.0 [ 0.0, 0.0 ]
Total (95% CI) 218 224 0.0 [ 0.0, 0.0 ]
Total events: 0 (Pharmacological), 0 (Mechanical)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pharmacologycal Favours mechanical
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Analysis 11.4. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis),
Outcome 4 Bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis)
Outcome: 4 Bleeding
Study or subgroup Pharmacological Mechanical Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 13/218 8/224 100.0 % 1.67 [ 0.71, 3.95 ]
Total (95% CI) 218 224 100.0 % 1.67 [ 0.71, 3.95 ]
Total events: 13 (Pharmacological), 8 (Mechanical)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pharmacologycal Favours mechanical
Analysis 11.5. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis),
Outcome 5 Major bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis)
Outcome: 5 Major bleeding
Study or subgroup Pharmacological Mechanical Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 4/218 4/224 100.0 % 1.03 [ 0.26, 4.06 ]
Total (95% CI) 218 224 100.0 % 1.03 [ 0.26, 4.06 ]
Total events: 4 (Pharmacological), 4 (Mechanical)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pharmacologycal Favours mechanical
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Analysis 11.6. Comparison 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis),
Outcome 6 Minor bleeding.
Review: Thromboprophylaxis for trauma patients
Comparison: 11 Pharmacological prophylaxis vs Mechanical prophylaxis (Sensitivity analysis)
Outcome: 6 Minor bleeding
Study or subgroup Pharmacological Mechanical Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ginzburg 2003 9/218 4/224 100.0 % 2.31 [ 0.72, 7.40 ]
Total (95% CI) 218 224 100.0 % 2.31 [ 0.72, 7.40 ]
Total events: 9 (Pharmacological), 4 (Mechanical)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pharmacologycal Favours mechanical
A P P E N D I C E S
Appendix 1. Search strategy
Cochrane Injuries Group Specialised Register (searched April 30 2009)
1. (wound* or trauma* or injur* or fracture* or burn* or stab* or shot* or shoot* or lacerat* or accident*)
2. (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or thromboph*) or ((deep* and (vein* or ven*) and
(thromb* or embol*)) or ((pulmonary or lung*) and (thromb* or embol*)) or (DVT or PE or VTE)
3. 1 and 2
4. Thromboprophylaxis or prophylactic* or prophylaxis or Heparin* or Anticoagulant* or Warfarin or Coumadin* or apo-warfarin or
gen-warfarin or warfant or Coumadin or aldocumar or tedicumar or Antiplatelet* or anticoagulant* or Aspirin* or “acetylsalicylic acid”
or acylpyrin or aloxiprimum or colfarit or dispril or easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna
or solprin or solupsan or zorprin or acetysal or Pentassacharide* or fondaparinux or Heparin* or “vena cava filter” or “umbrella filter”
anti-platelet*
5. 3 and 4
MEDLINE (Ovid) 1950 to April (Week 3) 2009
1. exp “Wounds and Injuries”/
2. (wound* or trauma* or injur* or fracture* or burn* or stab* or shot* or shoot* or lacerat* or accident*).mp. [mp=title, abstract,
subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
3. 1 or 2
4. exp Venous Thromboembolism/
5. exp Venous Thrombosis/
6. exp Pulmonary embolism/
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7. exp Thrombophlebitis/
8. (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or thromboph*).ab,ti.
9. (deep* adj3 (vein* or ven*) adj5 (thromb* or embol*)).ab,ti.
10. ((pulmonary or lung*) adj3 (thromb* or embol*)).ab,ti.
11. (DVT or PE or VTE).ab,ti.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. (thromboprophylaxis or prophylactic* or prophylaxis).ab,ti.
14. exp Heparin/
15. exp Heparin, Low-Molecular-Weight/
16. exp Heparinoids/
17. exp Stockings, Compression/
18. exp Intermittent Pneumatic Compression Devices/
19. exp Stockings, Compression/
20. exp Anticoagulants/
21. exp Warfarin/
22. exp Platelet Aggregation Inhibitors/
23. exp Aspirin/
24. Heparin*.ab,ti.
25. ((compression or impulse or pneumatic or elastic*) adj3 (device* or stocking* or hose* or dressing* or bandage*)).ab,ti.
26. (Anticoagulant* or Warfarin or Coumadin* or apo-warfarin or gen-warfarin or warfant or Coumadin or aldocumar or te-
dicumar).ab,ti.
27. (Antiplatelet* or (platelet* adj3 aggregation adj3 inhibit*) or ((blood or platelet*) adj3 (antagonist* or antiaggrega*))).ab,ti.
28. (Aspirin* or acetylsalicylic acid or acylpyrin or aloxiprimum or colfarit or dispril or easprin or ecotrin or endosprin or magnecyl or
micristin or polopirin or polopiryna or solprin or solupsan or zorprin or acetysal).ab,ti.
29. exp Vena Cava Filters/
30. ((vena adj3 cava adj3 filter*) or (umbrella adj3 filter*)).ab,ti.
31. (Pentassacharide* or fondaparinux).ab,ti.
32. or/13-31
33. randomi?ed.ab,ti.
34. randomized controlled trial.pt.
35. controlled clinical trial.pt.
36. placebo.ab.
37. clinical trials as topic.sh.
38. randomly.ab.
39. trial.ti.
40. 33 or 34 or 35 or 36 or 37 or 38 or 39
41. (animals not (humans and animals)).sh.
42. 40 not 41
43. 3 and 12 and 32 and 42
EMBASE (Ovid) 1980 to 2009 (Week 17)
1.exp Injury/
2.(wound* or trauma* or injur* or fracture* or burn* or stab* or shot* or shoot* or lacerat* or accident*).mp. [mp=title, abstract,





7.exp deep vein thrombosis/
8.exp Thrombophlebitis/
9.(thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or thromboph*).ab,ti.
10.(deep* adj3 (vein* or ven*) adj5 (thromb* or embol*)).ab,ti.
11.(deep* adj3 (vein* or ven*) adj5 (thromb* or embol*)).ab,ti.
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12.((pulmonary or lung*) adj3 (thromb* or embol*)).ab,ti.
13.(DVT or PE or VTE).ab,ti.
14.or/4-13
15.(thromboprophylaxis or prophylactic* or prophylaxis).ab,ti.
16.exp Heparin/




21.exp intermittent pneumatic compression device/






28.(Anticoagulant* or Warfarin or Coumadin* or apo-warfarin or gen-warfarin or warfant or Coumadin or aldocumar or te-
dicumar).ab,ti.
29.(Antiplatelet* or (platelet* adj3 aggregation adj3 inhibit*) or ((blood or platelet*) adj3 (antagonist* or antiaggrega*))).ab,ti.
30.(Aspirin* or acetylsalicylic acid or acylpyrin or aloxiprimum or colfarit or dispril or easprin or ecotrin or endosprin or magnecyl or
micristin or polopirin or polopiryna or solprin or solupsan or zorprin or acetysal).ab,ti.
31.((vena adj3 cava adj3 filter*) or (umbrella adj3 filter*)).ab,ti.
32.(Pentassacharide* or fondaparinux).ab,ti.
33.((compression or impulse or pneumatic or elastic*) adj3 (device* or stocking* or hose* or dressing* or bandage*)).ab,ti.
34.or/15-33
35.exp Randomized Controlled Trial/






42.35 or 36 or 37 or 38 or 39 or 40 or 41
43.exp animal/ not (exp human/ and exp animal/)
44.42 not 43
45.34 and 3 and 44 and 14
CENTRAL (The Cochrane Library 2009, Issue 2)
#1 MeSH descriptor Venous Thromboembolism explode all trees
#2 MeSH descriptor Venous Thrombosis explode all trees
#3 MeSH descriptor Pulmonary Embolism explode all trees
#4 MeSH descriptor Thrombophlebitis explode all trees
#5 (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or thromboph*)
#6 ((deep*) near3 (vein* or ven*)) near5 (thromb* or embol*)
#7 (pulmonary or lung*) near3 (thromb* or embol*)
#8 DVT or PE or VTE
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 thromboprophylaxis or prophylactic* or prophylaxis
#11 MeSH descriptor Heparin explode all trees
#12 MeSH descriptor Heparin, Low-Molecular-Weight explode all trees
#13 MeSH descriptor Heparinoids explode all trees
#14 MeSH descriptor Stockings, Compression explode all trees
#15 MeSH descriptor Intermittent Pneumatic Compression Devices explode all trees
#16 MeSH descriptor Stockings, Compression explode all trees
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#17 MeSH descriptor Anticoagulants explode all trees
#18 MeSH descriptor Warfarin explode all trees
#19 MeSH descriptor Platelet Aggregation Inhibitors explode all trees
#20 MeSH descriptor Aspirin explode all trees
#21 Heparin*
#22 ((compression or impulse or pneumatic or elastic*) near3 (device* or stocking* or hose* or dressing* or bandage*))
#23 (Anticoagulant* or Warfarin or Coumadin* or apo-warfarin or gen-warfarin or warfant or Coumadin or aldocumar or tedicumar)
#24 Antiplatelet* or (platelet* near3 aggregation near3 inhibit*)
#25 (blood or platelet*) near3 (antagonist* or antiaggrega*)
#26 Aspirin* or acetylsalicylic acid or acylpyrin or aloxiprimum or colfarit or dispril or easprin or ecotrin or endosprin or magnecyl or
micristin or polopirin or polopiryna or solprin or solupsan or zorprin or acetysal
#27 MeSH descriptor Vena Cava Filters explode all trees
#28 (vena near3 cava near3 filter*) or (umbrella near3 filter*)
#29 Pentassacharide* or fondaparinux
#30 (#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24
OR #25 OR #26 OR #27 OR #28 OR #29)
#31 (#9 AND #30)
#32 MeSH descriptor Wounds and Injuries explode all trees
#33 wound* or trauma* or injur* or fracture* or burn* or stab* or shot* or shoot* or lacerat* or accident*
#34 (#32 OR #33)
#35 (#31 AND #34)
ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) (1970 to April 2009),
ISI Web of Science: Conference Proceedings Citation Index-Science (CPCI-S) (1990 to April 2009)
#1 Topic=(wound* or trauma* or injur* or fracture* or burn* or stab* or shot* or shoot* or lacerat* or accident*)
#2 Topic=(thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or thromboph*) OR Topic=(deep* same (vein*
or ven*) same (thromb* or embol*)) OR Topic=((pulmonary or lung*) same (thromb* or embol*)) OR Topic=(DVT or PE or VTE)
#3 #1 and #2
#4 Topic=(thromboprophylaxis or prophylactic* or prophylaxis or Heparin* or Anticoagulant* or Warfarin or Coumadin* or apo-
warfarin or gen-warfarin or warfant or Coumadin or aldocumar or tedicumar or Antiplatelet* or Aspirin* or acetylsalicylic acid or
acylpyrin or aloxiprimum or colfarit or dispril or easprin or ecotrin or endosprin or magnecyl or micristin or polopirin or polopiryna
or solprin or solupsan or zorprin or acetysal or Pentassacharide* or fondaparinux)
#5 Topic=(platelet* same aggregation same inhibit*) OR Topic=((blood or platelet*) same (antagonist* or antiaggrega*)) OR Topic=
((compression or impulse or pneumatic or elastic*) same (device* or stocking* or hose* or dressing* or bandage*)) OR Topic=(vena
same cava same filter*) OR Topic=(umbrella same filter*)
#6 #4 or #5
#7 #3 and #6
#8Topic=(((singl*ORdoubl*OR trebl*OR tripl*) SAME (blind*ORmask*)))ORTopic=(randomisedOR randomizedOR randomly
OR random order OR random sequence OR random allocation OR randomly allocated OR at random OR randomized controlled
trial) OR Topic=(controlled clinical trial OR controlled trial OR clinical trial OR placebo) AND Topic=(human*)
#9 #7 and #8
PubMed [http://www.ncbi.nlm.nih.gov/sites/entrez] (searched 29 April 2009: limited to: added to PubMed in the Last 180
days)
#1 wound* OR trauma OR traumatic OR traumas OR traumatolog* OR injur* OR fracture* OR burn* OR stab OR stabbing* OR
stabbed OR stabwound* OR stabs OR shot* OR shoot* OR lacerat* OR accident*
#2 thrombus* OR thrombotic* OR thrombolic* OR thromboemboli* OR thrombos* OR thromboph*
#3 DVT OR PE OR VTE
#4 deep* AND (vein* OR venous) AND (thrombos OR thromboe* OR emboli*)
#5 #2 OR #3 OR #4
#6 (hromboprophylaxis OR prophylactic* OR prophylaxis OR Heparin* OR Anticoagulant* ORWarfarin OR Coumadin* OR apo-
warfarin OR gen-warfarin OR warfant ORCoumadin OR aldocumar OR tedicumar OR Antiplatelet* OR Aspirin* OR acetylsalicylic
acid OR acylpyrin OR aloxiprimum OR colfarit OR dispril OR easprin OR ecotrin OR endosprin OR magnecyl OR micristin OR
polopirin OR polopiryna OR solprin OR solupsan OR zorprin OR acetysal OR Pentassacharide* OR fondaparinux
#7 platelet* AND aggregation AND inhibitor*
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#8 (blood or platelet*) AND (antagonist* or antiaggrega*)
#9 (compression OR impulse OR pneumatic OR elastic*) AND (device* OR stocking* OR hose* OR dressing* OR bandage*)
#10 (vena AND cava AND filter*) OR (umbrella AND filter*)
#11 #6 OR #7 OR #8 OR #9 OR #10
#12 #1 AND #5 AND #11
#13 ((randomized controlled trial[pt] OR controlled clinical trial[pt]) OR (randomized OR randomised OR randomly OR
placebo[tiab]) OR (trial[ti]) OR (“Clinical Trials as Topic”[MeSHMajor Topic])) NOT ((“Animals”[Mesh]) NOT (“Humans”[Mesh]
AND “Animals”[Mesh]))
#14 #12 AND #13
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